GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: November 8, 2004, 15:22:46 ; Search time 0.001 Seconds
(without alignments)
51.700 Million cell updates/sec

Title: us-10-655-847-18
Perfect score: 50
Sequence: 1 ttcagagcaaaagacttgag.....aaacactaagctctctgggc 50

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 41 seqs, 517 residues

Total number of hits satisfying chosen parameters: 82

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 41 summaries

Database : rgedb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
c 1	14.4	28.8	18	1	CQ807902	ACCESSION:CQ807902
c 2	14.4	28.8	18	1	AX599526	ACCESSION:AX599526
c 3	14.4	28.8	18	1	AX767860	ACCESSION:AX767860
c 4	14.4	28.8	18	1	AX796438	ACCESSION:AX796438
c 5	14.4	28.8	18	1	AX822902	ACCESSION:AX822902
c 6	14.4	28.8	18	1	AX826542	ACCESSION:AX826542
7	13.8	27.6	17	1	AR192542	ACCESSION:AR192542
8	13.8	27.6	17	1	AR326411	ACCESSION:AR326411
c 9	12	24.0	15	1	AR056349	ACCESSION:AR056349
c 10	12	24.0	15	1	AR114107	ACCESSION:AR114107
c 11	12	24.0	15	1	AX633574	ACCESSION:AX633574
c 12	10	20.0	11	1	CQ833190	ACCESSION:CQ833190
13	10	20.0	11	1	AR488865	ACCESSION:AR488865
c 14	10	20.0	11	1	AX624234	ACCESSION:AX624234
c 15	10	20.0	11	1	AX625852	ACCESSION:AX625852
c 16	10	20.0	11	1	AX631655	ACCESSION:AX631655
17	9.4	18.8	11	1	AR030085	ACCESSION:AR030085
c 18	9.4	18.8	11	1	CQ832709	ACCESSION:CQ832709
c 19	9.4	18.8	11	1	CQ833046	ACCESSION:CQ833046
c 20	9.4	18.8	11	1	CQ833052	ACCESSION:CQ833052
21	9.4	18.8	11	1	CQ833935	ACCESSION:CQ833935
c 22	9.4	18.8	11	1	CQ835229	ACCESSION:CQ835229
23	9.4	18.8	11	1	AR301608	ACCESSION:AR301608
24	9.4	18.8	11	1	AR367536	ACCESSION:AR367536
25	9.4	18.8	11	1	AR367551	ACCESSION:AR367551
26	9.4	18.8	11	1	AX098787	ACCESSION:AX098787
c 27	9.4	18.8	11	1	AX098788	ACCESSION:AX098788
28	9.4	18.8	11	1	AX470435	ACCESSION:AX470435
c 29	9.4	18.8	11	1	AX470746	ACCESSION:AX470746
c 30	9.4	18.8	11	1	AX624408	ACCESSION:AX624408
c 31	9.4	18.8	11	1	AX624704	ACCESSION:AX624704
32	9.4	18.8	11	1	AX624745	ACCESSION:AX624745
c 33	9.4	18.8	11	1	AX626378	ACCESSION:AX626378
c 34	9.4	18.8	11	1	AX626388	ACCESSION:AX626388
35	9.4	18.8	11	1	AX627142	ACCESSION:AX627142
c 36	9.4	18.8	11	1	AX627434	ACCESSION:AX627434
37	9.4	18.8	11	1	AX627701	ACCESSION:AX627701
c 38	9.4	18.8	11	1	AX631829	ACCESSION:AX631829
c 39	9.4	18.8	11	1	AX632125	ACCESSION:AX632125
40	9.4	18.8	11	1	AX632166	ACCESSION:AX632166
41	9.4	18.8	11	1	BD124358	ACCESSION:BD124358

ALIGNMENTS

RESULT 1
CQ807902/c
LOCUS CQ807902 18 bp DNA linear PAT 10-MAY-2004
DEFINITION Sequence 1352 from Patent WO2004035803.
ACCESSION CQ807902
VERSION CQ807902.1 GI:47113296
KEYWORDS .
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Foekens,J., Harbeck,N., Koenig,T., Maier,S., Martens,J., Model,F., Nimmrich,I., Rujan,T., Schmitt,A., Schmitt,M., Look,M.P. and Marx,A.
TITLE Method and nucleic acids for the improved treatment of breast cell proliferative disorders
JOURNAL Patent: WO 2004035803-A 1352 29-APR-2004;
Epigenomics AG (DE)
FEATURES Location/Qualifiers
source 1. .18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Detection oligonucleotide for CDKN1C"

Query Match 28.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.2;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2079 TCCAAAGAAACACTAA 2094
||||||.|||||||||
Db 16 TCCAAACAAACACTAA 1

RESULT 2
AX599526/c
LOCUS AX599526 18 bp DNA linear PAT 14-FEB-2003
DEFINITION Sequence 866 from Patent WO02077272.
ACCESSION AX599526
VERSION AX599526.1 GI:28399670
KEYWORDS .
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J., Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E., Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T., Pelet,C. and Ziebarth,H.
TITLE Methods and nucleic acids for the analysis of hematopoietic cell proliferative disorders
JOURNAL Patent: WO 02077272-A 866 03-OCT-2002;
Epigenomics AG (DE)
FEATURES Location/Qualifiers
source 1. .18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Detection oligonucleotide for CDKN1C"

```
  Query Match            28.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 2.2;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2079 TCCAAAGAAACACTAA 2094
              |||||| |||||||||
Db         16 TCCAAACAAACACTAA 1


RESULT 3
AX767860/c
LOCUS       AX767860                  18 bp    DNA     linear   PAT 02-JUL-2003
DEFINITION  Sequence 508 from Patent WO03044226.
ACCESSION   AX767860
VERSION     AX767860.1  GI:32436546
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Burger,M., Caldwell,C., Genc,B., Becker,E., Maier,S. and
            Nimmrich,I.
  TITLE     Method and nucleic acids for the analysis of a lymphoid cell
            proliferative disorder
  JOURNAL   Patent: WO 03044226-A 508 30-MAY-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDKN1C"

  Query Match            28.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 2.2;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2079 TCCAAAGAAACACTAA 2094
              |||||| |||||||||
Db         16 TCCAAACAAACACTAA 1


RESULT 4
AX796438/c
LOCUS       AX796438                  18 bp    DNA     linear   PAT 04-OCT-2003
DEFINITION  Sequence 781 from Patent WO03052135.
ACCESSION   AX796438
VERSION     AX796438.1  GI:37517104
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Burger,M., Field,J.K., Genc,B., Liloglou,T., Lipscher,E., Maier,S.
            and Nimmrich,I.
  TITLE     Method and nucleic acids for the analysis of a lung cell
            proliferative disorder
  JOURNAL   Patent: WO 03052135-A 781 26-JUN-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDKN1C"

  Query Match            28.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 2.2;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2079 TCCAAAGAAACACTAA 2094
              |||||| |||||||||
Db         16 TCCAAACAAACACTAA 1


RESULT 5
AX822902/c
LOCUS       AX822902                  18 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 794 from Patent EP1340818.
ACCESSION   AX822902
VERSION     AX822902.1  GI:39749538
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Adorjan,P., Burger,M., Maier,S., Nimmrich,I., Becker,E., Lesche,R.,
            Rujan,T. and Schmitt,A.
  TITLE     Method and nucleic acids for the analysis of a colon cell
            proliferative disorder
  JOURNAL   Patent: EP 1340818-A 794 03-SEP-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDKN1C"

  Query Match            28.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 2.2;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2079 TCCAAAGAAACACTAA 2094
              |||||| |||||||||
Db         16 TCCAAACAAACACTAA 1


RESULT 6
AX826542/c
LOCUS       AX826542                  18 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 794 from Patent WO03072821.
ACCESSION   AX826542
VERSION     AX826542.1  GI:39752056
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Adorjan,P., Burger,M., Maier,S., Nimmrich,I., Becker,E., Lesche,R.,
            Rujan,T. and Schmitt,A.
  TITLE     Method and nucleic acids for the analysis of a colon cell
            proliferactive disorder
  JOURNAL   Patent: WO 03072821-A 794 04-SEP-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDKN1C"

  Query Match            28.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 2.2;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2079 TCCAAAGAAACACTAA 2094
              |||||| |||||||||
Db         16 TCCAAACAAACACTAA 1


RESULT 7
AR192542
LOCUS       AR192542                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 8030 from patent US 6346398.
ACCESSION   AR192542
```

```
VERSION     AR192542.1  GI:20238507
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 8030 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             27.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2.9;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2072 TGAGCCATCCAAAGAAA 2088
              ||||||||| |||| ||
Db          1 TGAGCCATCAAAAGGAA 17


RESULT 8
AR326411
LOCUS       AR326411                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 3813 from patent US 6566127.
ACCESSION   AR326411
VERSION     AR326411.1  GI:33712219
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 3813 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             27.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2.9;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2072 TGAGCCATCCAAAGAAA 2088
              ||||||||| |||| ||
Db          1 TGAGCCATCAAAAGGAA 17

1026

RESULT 9
AR056349/c
LOCUS       AR056349                  15 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 553 from patent US 5837542.
ACCESSION   AR056349
VERSION     AR056349.1  GI:5981926
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL   Patent: US 5837542-A 553 17-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"
```

ribozyme

```
  Query Match             24.0%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 6.2;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2058 CAGAGCAAAAGA 2069
              ||||||||||||
Db         14 CAGAGCAAAAGA 3


RESULT 10
AR114107/c
LOCUS       AR114107                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 553 from patent US 6132967.
ACCESSION   AR114107
VERSION     AR114107.1  GI:14094429
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Ribozyme treatment of diseases or conditions related to levels of
            intercellular adhesion molecule-1 (ICAM-1)
  JOURNAL   Patent: US 6132967-A 553 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"
```

1026

```
  Query Match             24.0%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 6.2;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2058 CAGAGCAAAAGA 2069
              ||||||||||||
Db         14 CAGAGCAAAAGA 3


RESULT 11
AX633574/c
LOCUS       AX633574                  15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 713 from Patent EP1260586.
ACCESSION   AX633574
VERSION     AX633574.1  GI:28469188
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 713 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             24.0%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 6.2;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2058 CAGAGCAAAAGA 2069
              ||||||||||||
Db         14 CAGAGCAAAAGA 3
```

```
RESULT 12
CQ833190/c
LOCUS       CQ833190                  11 bp    DNA     linear   PAT 29-JUL-2004
DEFINITION  Sequence 561 from Patent WO2004059002.
ACCESSION   CQ833190
VERSION     CQ833190.1  GI:50832797
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
            Conradt,M. and Hofmann,K.
  TITLE     Method for determining the homeostasis of hairy skin
  JOURNAL   Patent: WO 2004059002-A 561 15-JUL-2004;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             20.0%;  Score 10;  DB 1;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2068 GACTTGAGCC 2077
              ||||||||||
Db         11 GACTTGAGCC 2


RESULT 13
AR488865
LOCUS       AR488865                  11 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 94 from patent US 6709817.
ACCESSION   AR488865
VERSION     AR488865.1  GI:47255063
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 11)
  AUTHORS   Zoghbi,H.Y., Van den Veyver,I.B., Amir,R. and Francke,U.
  TITLE     Method of screening Rett syndrome by detecting a mutation in MECP2
  JOURNAL   Patent: US 6709817-A 94 23-MAR-2004;
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             20.0%;  Score 10;  DB 1;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2059 AGAGCAAAAG 2068
              ||||||||||
Db          1 AGAGCAAAAG 10


RESULT 14
AX624234/c
LOCUS       AX624234                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 1275 from Patent WO02053774.
ACCESSION   AX624234
VERSION     AX624234.1  GI:28452175
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 1275 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             20.0%;  Score 10;  DB 1;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAG 2095
              ||||||||||
Db         10 AAACACTAAG 1


RESULT 15
AX625852/c
LOCUS       AX625852                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 2893 from Patent WO02053774.
ACCESSION   AX625852
VERSION     AX625852.1  GI:28453890
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 2893 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             20.0%;  Score 10;  DB 1;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2074 AGCCATCCAA 2083
              ||||||||||
Db         11 AGCCATCCAA 2


RESULT 16
AX631655/c
LOCUS       AX631655                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 8697 from Patent WO02053774.
ACCESSION   AX631655
VERSION     AX631655.1  GI:28459731
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 8697 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             20.0%;  Score 10;  DB 1;  Length 11;
```

```
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAG 2095
              ||||||||||
Db         10 AAACACTAAG 1


RESULT 17
AR030085
LOCUS       AR030085                 11 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 274 from patent US 5861244.
ACCESSION   AR030085
VERSION     AR030085.1  GI:5943299
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 11)
  AUTHORS   Wang,C.-G. and Hepburn,A.G.
  TITLE     Genetic sequence assay using DNA triple strand formation
  JOURNAL   Patent: US 5861244-A 274 19-JAN-1999;
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2080 CCAAAGAAACA 2090
              ||||| |||||
Db          1 CCAAACAAACA 11


RESULT 18
CQ832709/c
LOCUS       CQ832709                 11 bp    DNA     linear   PAT 29-JUL-2004
DEFINITION  Sequence 80 from Patent WO2004059002.
ACCESSION   CQ832709
VERSION     CQ832709.1  GI:50832316
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
            Conradt,M. and Hofmann,K.
  TITLE     Method for determining the homeostasis of hairy skin
  JOURNAL   Patent: WO 2004059002-A 80 15-JUL-2004;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAGC 2096
              |||||||| ||
Db         11 AAACACTATGC 1


RESULT 19
CQ833046/c
LOCUS       CQ833046                 11 bp    DNA     linear   PAT 29-JUL-2004
DEFINITION  Sequence 417 from Patent WO2004059002.
ACCESSION   CQ833046
VERSION     CQ833046.1  GI:50832653
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
            Conradt,M. and Hofmann,K.
  TITLE     Method for determining the homeostasis of hairy skin
  JOURNAL   Patent: WO 2004059002-A 417 15-JUL-2004;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2058 CAGAGCAAAAG 2068
              |||| ||||||
Db         11 CAGAACAAAAG 1


RESULT 20
CQ833052/c
LOCUS       CQ833052                 11 bp    DNA     linear   PAT 29-JUL-2004
DEFINITION  Sequence 423 from Patent WO2004059002.
ACCESSION   CQ833052
VERSION     CQ833052.1  GI:50832659
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
            Conradt,M. and Hofmann,K.
  TITLE     Method for determining the homeostasis of hairy skin
  JOURNAL   Patent: WO 2004059002-A 423 15-JUL-2004;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAGC 2096
              ||||| |||||
Db         11 AAACATTAAGC 1


RESULT 21
CQ833935
LOCUS       CQ833935                 11 bp    DNA     linear   PAT 29-JUL-2004
DEFINITION  Sequence 1306 from Patent WO2004059002.
ACCESSION   CQ833935
VERSION     CQ833935.1  GI:50833542
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
            Conradt,M. and Hofmann,K.
```

```
  TITLE     Method for determining the homeostasis of hairy skin
  JOURNAL   Patent: WO 2004059002-A 1306 15-JUL-2004;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match           18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2071 TTGAGCCATCC 2081
              ||||||||  ||
Db          1 TTGAGCCAGCC 11


RESULT 22
CQ835229/c
LOCUS       CQ835229                 11 bp    DNA     linear   PAT 29-JUL-2004
DEFINITION  Sequence 287 from Patent WO2004059001.
ACCESSION   CQ835229
VERSION     CQ835229.1  GI:50834763
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
            Conradt,M. and Hofmann,K.
  TITLE     Method for determining markers of human facial skin
  JOURNAL   Patent: WO 2004059001-A 287 15-JUL-2004;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match           18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2093 AAGCTCTCTGG 2103
              |||  |||||||
Db         11 AAGTTCTCTGG 1


RESULT 23
AR301608
LOCUS       AR301608                 11 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 189 from patent US 6538173.
ACCESSION   AR301608
VERSION     AR301608.1  GI:31689410
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 11)
  AUTHORS   Heber-Katz,E.
  TITLE     Compositions and methods for wound healing
  JOURNAL   Patent: US 6538173-A 189 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match           18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2087 AACACTAAGCT 2097
              |||||  |||||
Db          1 AACACCAAGCT 11


RESULT 24
AR367536
LOCUS       AR367536                 11 bp    DNA     linear   PAT 12-SEP-2003
DEFINITION  Sequence 17 from patent US 6375954.
ACCESSION   AR367536
VERSION     AR367536.1  GI:34600847
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 11)
  AUTHORS   Dutta,S., Biswas,B. and Vemulapalli,R.
  TITLE     Size-variable strain-specific protective antigen for potomac horse
            fever
  JOURNAL   Patent: US 6375954-A 17 23-APR-2002;
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match           18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2082 AAAGAAACACT 2092
              |||||||  |||
Db          1 AAAGAAATACT 11


RESULT 25
AR367551
LOCUS       AR367551                 11 bp    DNA     linear   PAT 12-SEP-2003
DEFINITION  Sequence 32 from patent US 6375954.
ACCESSION   AR367551
VERSION     AR367551.1  GI:34600862
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 11)
  AUTHORS   Dutta,S., Biswas,B. and Vemulapalli,R.
  TITLE     Size-variable strain-specific protective antigen for potomac horse
            fever
  JOURNAL   Patent: US 6375954-A 32 23-APR-2002;
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match           18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2082 AAAGAAACACT 2092
              |||||||  |||
Db          1 AAAGAAATACT 11


RESULT 26
AX098787
LOCUS       AX098787                 11 bp    DNA     linear   PAT 02-APR-2001
DEFINITION  Sequence 94 from Patent WO0120025.
ACCESSION   AX098787
VERSION     AX098787.1  GI:13538028
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
```

```
REFERENCE   1
  AUTHORS   Wojnowski,L. and Eiselt,R.
  TITLE     Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in
            diagnostic and therapeutic applications
  JOURNAL   Patent: WO 0120025-A 94 22-MAR-2001;
            Epidauros Biotechnologie AG (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="artificial"

  Query Match           18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2085 GAAACACTAAG 2095
              |||||||| ||
Db          1 GAAACACTCAG 11
```

1026

```
RESULT 27
AX098788/c
LOCUS       AX098788                  11 bp    DNA     linear   PAT 02-APR-2001
DEFINITION  Sequence 95 from Patent WO0120025.
ACCESSION   AX098788
VERSION     AX098788.1  GI:13538029
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Wojnowski,L. and Eiselt,R.
  TITLE     Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in
            diagnostic and therapeutic applications
  JOURNAL   Patent: WO 0120025-A 95 22-MAR-2001;
            Epidauros Biotechnologie AG (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="artificial"

  Query Match           18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2085 GAAACACTAAG 2095
              |||||||| ||
Db         11 GAAACACTCAG 1


RESULT 28
AX470435
LOCUS       AX470435                  11 bp    DNA     linear   PAT 09-AUG-2002
DEFINITION  Sequence 12 from Patent WO02053773.
ACCESSION   AX470435
VERSION     AX470435.1  GI:22205560
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Hofmann,K., Conradt,M. and Petersohn,D.
  TITLE     Method for determining skin stress or skin ageing in vitro
  JOURNAL   Patent: WO 02053773-A 12 11-JUL-2002;
            HENKEL KGAA (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match           18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2071 TTGAGCCATCC 2081
              |||||||| ||
Db          1 TTGAGCCAGCC 11


RESULT 29
AX470746/c
LOCUS       AX470746                  11 bp    DNA     linear   PAT 09-AUG-2002
DEFINITION  Sequence 323 from Patent WO02053773.
ACCESSION   AX470746
VERSION     AX470746.1  GI:22205871
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Hofmann,K., Conradt,M. and Petersohn,D.
  TITLE     Method for determining skin stress or skin ageing in vitro
  JOURNAL   Patent: WO 02053773-A 323 11-JUL-2002;
            HENKEL KGAA (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match           18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2056 TTCAGAGCAAA 2066
              ||||||| |||
Db         11 TTCAGAGAAAA 1


RESULT 30
AX624408/c
LOCUS       AX624408                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 1449 from Patent WO02053774.
ACCESSION   AX624408
VERSION     AX624408.1  GI:28452349
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 1449 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match           18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2057 TCAGAGCAAAA 2067
              || ||||||||
Db         11 TCTGAGCAAAA 1
```

```
RESULT 31
AX624704/c
LOCUS       AX624704                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 1745 from Patent WO02053774.
ACCESSION   AX624704
VERSION     AX624704.1  GI:28452645
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 1745 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2056 TTCAGAGCAAA 2066
              ||||||| |||
Db         11 TTCAGAGAAAA 1


RESULT 32
AX624745
LOCUS       AX624745                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 1786 from Patent WO02053774.
ACCESSION   AX624745
VERSION     AX624745.1  GI:28452686
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 1786 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2084 AGAAACACTAA 2094
              ||||||||| |
Db          1 AGAAACACTCA 11


RESULT 33
AX626378/c
LOCUS       AX626378                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 3419 from Patent WO02053774.
ACCESSION   AX626378
VERSION     AX626378.1  GI:28454416
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 3419 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAGC 2096
              ||||| |||||
Db         11 AAACATTAAGC 1


RESULT 34
AX626388/c
LOCUS       AX626388                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 3429 from Patent WO02053774.
ACCESSION   AX626388
VERSION     AX626388.1  GI:28454426
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 3429 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2093 AAGCTCTCTGG 2103
              ||| |||||||
Db         11 AAGTTCTCTGG 1


RESULT 35
AX627142
LOCUS       AX627142                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 4183 from Patent WO02053774.
ACCESSION   AX627142
VERSION     AX627142.1  GI:28455180
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 4183 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
```

```
  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2083 AAGAAACACTA 2093
              |||||| ||||
Db          1 AAGAAAGACTA 11


RESULT 36
AX627434/c
LOCUS       AX627434                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 4475 from Patent WO02053774.
ACCESSION   AX627434
VERSION     AX627434.1  GI:28455472
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 4475 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2058 CAGAGCAAAAG 2068
              |||| ||||||
Db         11 CAGAACAAAAG 1


RESULT 37
AX627701
LOCUS       AX627701                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 4742 from Patent WO02053774.
ACCESSION   AX627701
VERSION     AX627701.1  GI:28455739
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 4742 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2071 TTGAGCCATCC 2081
              |||||||| ||
Db          1 TTGAGCCAGCC 11


RESULT 38
AX631829/c
LOCUS       AX631829                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 8871 from Patent WO02053774.
ACCESSION   AX631829
VERSION     AX631829.1  GI:28459936
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 8871 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2057 TCAGAGCAAAA 2067
              || ||||||||
Db         11 TCTGAGCAAAA 1


RESULT 39
AX632125/c
LOCUS       AX632125                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 9167 from Patent WO02053774.
ACCESSION   AX632125
VERSION     AX632125.1  GI:28467740
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 9167 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2056 TTCAGAGCAAA 2066
              ||||||| |||
Db         11 TTCAGAGAAAA 1


RESULT 40
AX632166
LOCUS       AX632166                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 9208 from Patent WO02053774.
ACCESSION   AX632166
VERSION     AX632166.1  GI:28467781
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
```

```
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 9208 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2084 AGAAACACTAA 2094
              ||||||||| |
Db          1 AGAAACACTCA 11


RESULT 41
BD124358
LOCUS       BD124358                  11 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Compositions and method for healing wound.
ACCESSION   BD124358
VERSION     BD124358.1  GI:23219303
KEYWORDS    JP 2002503460-A/189.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 11)
  AUTHORS   Katz,E.H.
  TITLE     Compositions and method for healing wound
  JOURNAL   Patent: JP 2002503460-A 189 05-FEB-2002;
            THE WISTAR INSTITUTE
COMMENT     OS   Mus musculus (mouse)
            PN   JP 2002503460-A/189
            PD   05-FEB-2002
            PF   12-FEB-1999 JP 2000531545
            PR   13-FEB-1998 US    60/074737,26-AUG-1998 US    60/097937 PR
            28-SEP-1998 US    60/102051
            PI   ELLEN HEBER KATZ
            PC   C12N15/09,A01K67/027,C12N5/10,C12Q1/68,G01N33/50,C12N15/00, PC
              C12N5/00
            CC   Compositions and method for healing wound
            FH   Key             Location/Qualifiers
            FT   source          1. .11
            FT                   /organism='Mus musculus (mouse)'.
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:10090"

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 21;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2087 AACACTAAGCT 2097
              ||||| |||||
Db          1 AACACCAAGCT 11


Search completed: November  8, 2004, 15:22:46
Job time : 0.001 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: November 8, 2004, 15:26:23 ; Search time 0.001 Seconds
(without alignments)
48.900 Million cell updates/sec

Title: us-10-655-847-18
Perfect score: 50
Sequence: 1 ttcagagcaaaagacttgag.....aaacactaagctctctgggc 50

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 46 seqs, 489 residues

Total number of hits satisfying chosen parameters: 92

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 46 summaries

Database : rnidb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	13.8	27.6	17	1	US-08-584-040-8030	Sequence 8030, Ap
	2	13.8	27.6	17	1	US-09-371-772B-3813	Sequence 3813, Ap
c	3	12	24.0	15	1	US-08-292-620A-553	Sequence 553, App
c	4	12	24.0	15	1	US-09-071-845-553	Sequence 553, App
c	5	10	20.0	10	1	US-08-388-353-415	Sequence 415, App
	6	10	20.0	10	1	US-08-388-353-702	Sequence 702, App
c	7	10	20.0	10	1	US-08-488-551B-415	Sequence 415, App
	8	10	20.0	10	1	US-08-488-551B-702	Sequence 702, App
	9	10	20.0	11	1	US-09-657-013-94	Sequence 94, Appl
	10	9.4	18.8	11	1	US-08-173-489C-274	Sequence 274, App
	11	9.4	18.8	11	1	US-09-157-257-17	Sequence 17, Appl
	12	9.4	18.8	11	1	US-09-157-257-32	Sequence 32, Appl
	13	9.4	18.8	11	1	US-09-249-155A-189	Sequence 189, App
	14	9	18.0	10	1	US-07-724-500B-4	Sequence 4, Appli
	15	9	18.0	10	1	US-08-461-418B-4	Sequence 4, Appli
c	16	9	18.0	10	1	US-08-388-353-32	Sequence 32, Appl
c	17	9	18.0	10	1	US-08-388-353-33	Sequence 33, Appl
c	18	9	18.0	10	1	US-08-388-353-414	Sequence 414, App
c	19	9	18.0	10	1	US-08-388-353-416	Sequence 416, App
	20	9	18.0	10	1	US-08-388-353-701	Sequence 701, App
	21	9	18.0	10	1	US-08-388-353-703	Sequence 703, App
c	22	9	18.0	10	1	US-08-488-551B-32	Sequence 32, Appl
c	23	9	18.0	10	1	US-08-488-551B-33	Sequence 33, Appl
c	24	9	18.0	10	1	US-08-488-551B-414	Sequence 414, App
c	25	9	18.0	10	1	US-08-488-551B-416	Sequence 416, App
	26	9	18.0	10	1	US-08-488-551B-701	Sequence 701, App
	27	9	18.0	10	1	US-08-488-551B-703	Sequence 703, App
c	28	9	18.0	10	1	US-09-034-205-50	Sequence 50, Appl
c	29	9	18.0	10	1	US-08-934-097A-50	Sequence 50, Appl
c	30	9	18.0	10	1	US-09-677-218B-50	Sequence 50, Appl
c	31	9	18.0	10	1	US-09-677-192-50	Sequence 50, Appl
	32	9	18.0	10	1	US-09-255-899-4	Sequence 4, Appli
c	33	9	18.0	10	1	US-09-402-618B-50	Sequence 50, Appl
c	34	9	18.0	10	1	US-09-825-574-50	Sequence 50, Appl
	35	9	18.0	10	1	PCT-US91-01822A-4	Sequence 4, Appli
	36	9	18.0	10	1	PCT-US91-02628-4	Sequence 4, Appli
	37	8.4	16.8	10	1	US-08-205-507-10	Sequence 10, Appl
	38	8.4	16.8	10	1	US-08-308-894-6	Sequence 6, Appli
c	39	8.4	16.8	10	1	US-08-808-474A-3	Sequence 3, Appli
	40	8.4	16.8	10	1	US-08-388-353-442	Sequence 442, App
c	41	8.4	16.8	10	1	US-08-388-353-585	Sequence 585, App
	42	8.4	16.8	10	1	US-08-488-551B-442	Sequence 442, App
c	43	8.4	16.8	10	1	US-08-488-551B-585	Sequence 585, App
	44	8.4	16.8	10	1	US-09-508-753B-166	Sequence 166, App
c	45	8.4	16.8	10	1	US-09-769-482-16	Sequence 16, Appl
c	46	8.4	16.8	10	1	US-09-822-250A-21	Sequence 21, Appl

ALIGNMENTS

RESULT 1
US-08-584-040-8030
; Sequence 8030, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 8030:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-8030

Query Match 27.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2072 TGAGCCATCCAAAGAAA 2088
              :|||||||:| |||| ||
Db          1 UGAGCCAUCAAAAGGAA 17


RESULT 2
US-09-371-772B-3813
; Sequence 3813, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3813
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3813

  Query Match             27.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 1;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2072 TGAGCCATCCAAAGAAA 2088
              :|||||||:| |||| ||
Db          1 UGAGCCAUCAAAAGGAA 17


RESULT 3
US-08-292-620A-553/c
; Sequence 553, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  553:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-553

  Query Match             24.0%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 2.8;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2058 CAGAGCAAAAGA 2069
              ||||||||||||
Db         14 CAGAGCAAAAGA 3


RESULT 4
US-09-071-845-553/c
; Sequence 553, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
```

; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 553:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-553

Query Match 24.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2058 CAGAGCAAAAGA 2069
||||||||||||
Db 14 CAGAGCAAAAGA 3

RESULT 5
US-08-388-353-415/c
; Sequence 415, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: DiGiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 415:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-388-353-415

1/4/00
1826

Query Match 20.0%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2076 CCATCCAAAG 2085
||||||||||
Db 10 CCATCCAAAG 1

RESULT 6
US-08-388-353-702
; Sequence 702, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: DiGiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 702:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-388-353-702

Query Match 20.0%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2094 AGCTCTCTGG 2103
||||||||||
Db 1 AGCTCTCTGG 10

RESULT 7
US-08-488-551B-415/c
; Sequence 415, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841

```
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;       STREET:  400 GARDEN CITY PLAZA
;       CITY:  GARDEN CITY
;       STATE:  NEW YORK
;       COUNTRY:  U.S.A.
;       ZIP:  11530-0299
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/488,551B
;       FILING DATE:  07-JUN-1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  PM3864 (AU)
;       FILING DATE:  14-FEB-1994
;       APPLICATION NUMBER:  PM4002 (AU)
;       FILING DATE:  21-FEB-1994
;       APPLICATION NUMBER:  PN0284 (AU)
;       FILING DATE:  23-DEC-1994
;       APPLICATION NUMBER:  US 08/388,353
;       FILING DATE:  14-FEB-1995
;       APPLICATION NUMBER:  PN3021/95
;       FILING DATE:  17-MAY-1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  FRANK S. DIGIGLIO
;       REFERENCE/DOCKET NUMBER:  9606Z
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (516) 742-4343
;       TELEFAX:  (516) 742-4366
;   INFORMATION FOR SEQ ID NO:  415:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  10 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA
US-08-488-551B-415

  Query Match             20.0%;  Score 10;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2076 CCATCCAAAG 2085
              ||||||||||
Db         10 CCATCCAAAG 1


RESULT 8
US-08-488-551B-702
; Sequence 702, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;     APPLICANT:  Nicholas J. Deacon
;     APPLICANT:  Dale A. McPhee
;     APPLICANT:  David Cooper
;     TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;     NUMBER OF SEQUENCES:  841
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;       STREET:  400 GARDEN CITY PLAZA
;       CITY:  GARDEN CITY
;       STATE:  NEW YORK
;       COUNTRY:  U.S.A.
;       ZIP:  11530-0299
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/488,551B
;       FILING DATE:  07-JUN-1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  PM3864 (AU)
;       FILING DATE:  14-FEB-1994
;       APPLICATION NUMBER:  PM4002 (AU)
;       FILING DATE:  21-FEB-1994
;       APPLICATION NUMBER:  PN0284 (AU)
;       FILING DATE:  23-DEC-1994
;       APPLICATION NUMBER:  US 08/388,353
;       FILING DATE:  14-FEB-1995
;       APPLICATION NUMBER:  PN3021/95
;       FILING DATE:  17-MAY-1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  FRANK S. DIGIGLIO
;       REFERENCE/DOCKET NUMBER:  9606Z
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (516) 742-4343
;       TELEFAX:  (516) 742-4366
;   INFORMATION FOR SEQ ID NO:  702:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  10 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA
US-08-488-551B-702

  Query Match             20.0%;  Score 10;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2094 AGCTCTCTGG 2103
              ||||||||||
Db          1 AGCTCTCTGG 10


RESULT 9
US-09-657-013-94
; Sequence 94, Application US/09657013
; Patent No. 6709817
; GENERAL INFORMATION:
;  APPLICANT: Zoghbi, Huda Y.
;  APPLICANT:  Van den Veyver, Ignatia B
;  APPLICANT:  Amir, Ruthie
;  APPLICANT:  Francke, Uta
;  TITLE OF INVENTION: Methods of Identifying Mutations in a Methyl-CPG-Binding Domain
;  TITLE OF INVENTION:  Containing Gene or Protein in Neurodevelopmental Disease and Trea
;  FILE REFERENCE: HO-P01893US1/09905371
;  CURRENT APPLICATION NUMBER: US/09/657,013
;  CURRENT FILING DATE:  2000-09-07
;  PRIOR APPLICATION NUMBER: US 60/152,778
;  PRIOR FILING DATE: 1999-09-07
;  NUMBER OF SEQ ID NOS: 114
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 94
;   LENGTH: 11
;   TYPE: DNA
;   ORGANISM: Human
US-09-657-013-94

  Query Match             20.0%;  Score 10;  DB 1;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 9.9;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2059 AGAGCAAAAG 2068
              ||||||||||
Db          1 AGAGCAAAAG 10


RESULT 10
US-08-173-489C-274
; Sequence 274, Application US/08173489C
```

```
; Patent No. 5861244
;  GENERAL INFORMATION:
;    APPLICANT:  WANG, C. -G.
;    APPLICANT:  HEPBURN, A. G.
;    TITLE OF INVENTION:  GENETIC SEQUENCE ASSAY USING DNA
;    TITLE OF INVENTION:  TRIPLE-STRAND FORMATION.
;    NUMBER OF SEQUENCES:  365
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PROFILE DIAGNOSTIC SCIENCES, INC.,
;      STREET:  510 EAST 73RD STREET,
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10021.
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44Mb storage
;      COMPUTER:  IBM PC/XT/AT
;      OPERATING SYSTEM:  MS-DOS version 6.2
;      SOFTWARE:  Wordperfect Version 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/173,489C
;      FILING DATE:  22 DEC 1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/968,436
;      FILING DATE:  29 OCT 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Handelman, Joseph H.
;      REGISTRATION NUMBER:  26,179
;      REFERENCE/DOCKET NUMBER:  U9518-6
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (attorney) (212) 708-1880
;      TELEFAX:  (attorney) (212) 246-8959
;  INFORMATION FOR SEQ ID NO:  274:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  11 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  third strand derived from A. faecalis
;      DESCRIPTION:  16s region in Seq ID No. 5861244273
;    HYPOTHETICAL:  yes
;    ANTI-SENSE:  no
;    PUBLICATION INFORMATION:
;      RELEVANT RESIDUES IN SEQ ID NO:  274 :FROM 1 TO 11
US-08-173-489C-274

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 13;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2080 CCAAAGAAACA 2090
             ||||| |||||
Db          1 CCAAACAAACA 11


RESULT 11
US-09-157-257-17
; Sequence 17, Application US/09157257
; Patent No. 6375954
; GENERAL INFORMATION:
;  APPLICANT: DUTTA, Sukanta K.
;  APPLICANT: BISWAS, Biswajit
;  APPLICANT: VEMULAPALLI, Ramesh
;  TITLE OF INVENTION: A SIZE-VARIABLE STRAIN-SPECIFIC PROTECTIVE ANTIGEN FOR
;  TITLE OF INVENTION: POTOMAC HORSE FEVER
;  FILE REFERENCE: 8172-9016
;  CURRENT APPLICATION NUMBER: US/09/157,257
;  CURRENT FILING DATE: 1998-09-18
;  EARLIER APPLICATION NUMBER: 60/059,252
;  EARLIER FILING DATE: 1997-09-18
;  NUMBER OF SEQ ID NOS: 48
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 17
;   LENGTH: 11
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
US-09-157-257-17

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 13;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2082 AAAGAAACACT 2092
              ||||||| |||
Db          1 AAAGAAATACT 11


RESULT 12
US-09-157-257-32
; Sequence 32, Application US/09157257
; Patent No. 6375954
; GENERAL INFORMATION:
;  APPLICANT: DUTTA, Sukanta K.
;  APPLICANT: BISWAS, Biswajit
;  APPLICANT: VEMULAPALLI, Ramesh
;  TITLE OF INVENTION: A SIZE-VARIABLE STRAIN-SPECIFIC PROTECTIVE ANTIGEN FOR
;  TITLE OF INVENTION: POTOMAC HORSE FEVER
;  FILE REFERENCE: 8172-9016
;  CURRENT APPLICATION NUMBER: US/09/157,257
;  CURRENT FILING DATE: 1998-09-18
;  EARLIER APPLICATION NUMBER: 60/059,252
;  EARLIER FILING DATE: 1997-09-18
;  NUMBER OF SEQ ID NOS: 48
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 32
;   LENGTH: 11
;   TYPE: DNA
;   ORGANISM: Ehrlichia risticii
US-09-157-257-32

  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 13;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2082 AAAGAAACACT 2092
              ||||||| |||
Db          1 AAAGAAATACT 11


RESULT 13
US-09-249-155A-189
; Sequence 189, Application US/09249155A
; Patent No. 6538173
; GENERAL INFORMATION:
;  APPLICANT:  Heber-Katz, Ellen
;  TITLE OF INVENTION:  Compositions and Methods for Wound
;  TITLE OF INVENTION:  Healing
;  FILE REFERENCE:  00486.78503
;  CURRENT APPLICATION NUMBER: US/09/249,155A
;  CURRENT FILING DATE:  1999-02-12
;  PRIOR APPLICATION NUMBER:  US 60/074,737
;  PRIOR FILING DATE:  1998-02-13
;  PRIOR APPLICATION NUMBER:  US 60/097,937
;  PRIOR FILING DATE:  1998-08-26
;  PRIOR APPLICATION NUMBER:  US 60/102,051
;  PRIOR FILING DATE:  1998-09-28
;  NUMBER OF SEQ ID NOS:  346
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 189
;   LENGTH: 11
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-09-249-155A-189
```

```
  Query Match             18.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 13;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2087 AACACTAAGCT 2097
              ||||| |||||
Db          1 AACACCAAGCT 11


RESULT 14
US-07-724-500B-4
; Sequence 4, Application US/07724500B
; Patent No. 5736294
;  GENERAL INFORMATION:
;    APPLICANT:  Ecker et al.
;    TITLE OF INVENTION:  REAGENTS AND METHODS FOR MODULATING GENE EXPRESSION THR
;    NUMBER OF SEQUENCES:  23
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz
;      ADDRESSEE:  Mackiewicz & No. 5736294ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/724,500B
;      FILING DATE:  June 27, 1991
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US91/01822
;      FILING DATE:  19 March 1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  John W. Caldwell
;      REGISTRATION NUMBER:  28,937
;      REFERENCE/DOCKET NUMBER:  ISIS-0309
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-07-724-500B-4

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   66.7%;  Pred. No. 17;
  Matches    6;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2095 GCTCTCTGG 2103
              ||:|:|:||
Db          1 GCUCUCUGG 9


RESULT 15
US-08-461-418B-4
; Sequence 4, Application US/08461418B
; Patent No. 5874564
;  GENERAL INFORMATION:
;    APPLICANT:  Ecker et al.
;    TITLE OF INVENTION:  Reagents And Methods For Modulating Gene
;    TITLE OF INVENTION:  Expression Through RNA Mimicry
;    NUMBER OF SEQUENCES:  17
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz & No. 5874564ris LLP
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch disk, 1.44 Mb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/461,418B
;      FILING DATE:  05-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/927,505
;      FILING DATE:  16-SEP-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul K. Legaard
;      REGISTRATION NUMBER:  38,534
;      REFERENCE/DOCKET NUMBER:  ISIS-1998
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-461-418B-4

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   66.7%;  Pred. No. 17;
  Matches    6;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2095 GCTCTCTGG 2103
              ||:|:|:||
Db          1 GCUCUCUGG 9


RESULT 16
US-08-388-353-32/c
; Sequence 32, Application US/08388353
; Patent No. 6010895
;  GENERAL INFORMATION:
;    APPLICANT:  Deacon, Nicholas J.
;    APPLICANT:  Learmont, Jennifer C.
;    APPLICANT:  McPhee, Dale A.
;    APPLICANT:  Crowe, Suzanne
;    APPLICANT:  Cooper, David
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  800
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/388,353
;      FILING DATE:  14-FEB-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
```

```
;       REGISTRATION NUMBER:  31,346
;       REFERENCE/DOCKET NUMBER:  9606
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (516) 742-4343
;       TELEFAX:  (516) 742-4366
;       TELEX:  230 901 SANS UR
;   INFORMATION FOR SEQ ID NO:  32:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  10 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
US-08-388-353-32

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2075 GCCATCCAA 2083
             |||||||||
Db         10 GCCATCCAA 2


RESULT 17
US-08-388-353-33/c
; Sequence 33, Application US/08388353
; Patent No. 6010895
;  GENERAL INFORMATION:
;    APPLICANT:  Deacon, Nicholas J.
;    APPLICANT:  Learmont, Jennifer C.
;    APPLICANT:  McPhee, Dale A.
;    APPLICANT:  Crowe, Suzanne
;    APPLICANT:  Cooper, David
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  800
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/388,353
;      FILING DATE:  14-FEB-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  9606
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  33:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-388-353-33

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2075 GCCATCCAA 2083
             |||||||||
Db         9 GCCATCCAA 1


RESULT 18
US-08-388-353-414/c
; Sequence 414, Application US/08388353
; Patent No. 6010895
;  GENERAL INFORMATION:
;    APPLICANT:  Deacon, Nicholas J.
;    APPLICANT:  Learmont, Jennifer C.
;    APPLICANT:  McPhee, Dale A.
;    APPLICANT:  Crowe, Suzanne
;    APPLICANT:  Cooper, David
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  800
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/388,353
;      FILING DATE:  14-FEB-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  9606
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  414:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-388-353-414

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2077 CATCCAAAG 2085
             |||||||||
Db         10 CATCCAAAG 2


RESULT 19
US-08-388-353-416/c
; Sequence 416, Application US/08388353
; Patent No. 6010895
;  GENERAL INFORMATION:
;    APPLICANT:  Deacon, Nicholas J.
;    APPLICANT:  Learmont, Jennifer C.
;    APPLICANT:  McPhee, Dale A.
;    APPLICANT:  Crowe, Suzanne
;    APPLICANT:  Cooper, David
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  800
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
```

```
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/388,353
;      FILING DATE:  14-FEB-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  9606
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  416:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-388-353-416

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2076 CCATCCAAA 2084
             |||||||||
Db          9 CCATCCAAA 1


RESULT 20
US-08-388-353-701
; Sequence 701, Application US/08388353
; Patent No. 6010895
;  GENERAL INFORMATION:
;    APPLICANT:  Deacon, Nicholas J.
;    APPLICANT:  Learmont, Jennifer C.
;    APPLICANT:  McPhee, Dale A.
;    APPLICANT:  Crowe, Suzanne
;    APPLICANT:  Cooper, David
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  800
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/388,353
;      FILING DATE:  14-FEB-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  9606
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  701:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-388-353-701

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2094 AGCTCTCTG 2102
             |||||||||
Db          2 AGCTCTCTG 10


RESULT 21
US-08-388-353-703
; Sequence 703, Application US/08388353
; Patent No. 6010895
;  GENERAL INFORMATION:
;    APPLICANT:  Deacon, Nicholas J.
;    APPLICANT:  Learmont, Jennifer C.
;    APPLICANT:  McPhee, Dale A.
;    APPLICANT:  Crowe, Suzanne
;    APPLICANT:  Cooper, David
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  800
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/388,353
;      FILING DATE:  14-FEB-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  9606
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  703:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-388-353-703

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2095 GCTCTCTGG 2103
             |||||||||
Db          1 GCTCTCTGG 9
```

```
RESULT 22
US-08-488-551B-32/c
; Sequence 32, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  32:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-32

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2075 GCCATCCAA 2083
              |||||||||
Db         10 GCCATCCAA 2


RESULT 23
US-08-488-551B-33/c
; Sequence 33, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  33:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-33

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2075 GCCATCCAA 2083
              |||||||||
Db          9 GCCATCCAA 1


RESULT 24
US-08-488-551B-414/c
; Sequence 414, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
```

```
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  414:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-414

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2077 CATCCAAAG 2085
              |||||||||
Db         10 CATCCAAAG 2


RESULT 25
US-08-488-551B-416/c
; Sequence 416, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  416:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-416

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2076 CCATCCAAA 2084
              |||||||||
Db          9 CCATCCAAA 1


RESULT 26
US-08-488-551B-701
; Sequence 701, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  701:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-701
```

```
  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2094 AGCTCTCTG 2102
             |||||||||
Db          2 AGCTCTCTG 10


RESULT 27
US-08-488-551B-703
; Sequence 703, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  703:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-703

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2095 GCTCTCTGG 2103
             |||||||||
Db          1 GCTCTCTGG 9


RESULT 28
US-09-034-205-50/c
; Sequence 50, Application US/09034205
; Patent No. 6194149
;  GENERAL INFORMATION:
;    APPLICANT:  Lyamichev, Victor I.
;    APPLICANT:  Brow, Mary Ann D.
;    APPLICANT:  Fors, Lance
;    APPLICANT:  Neri, Bruce P.
;    TITLE OF INVENTION:  TARGET-DEPENDENT REACTIONS USING
;    TITLE OF INVENTION:  STRUCTURE-BRIDGING OLIGONUCLEOTIDES
;    NUMBER OF SEQUENCES:  68
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MEDLEN & CARROLL, LLP
;      STREET:  220 Montgomery Street, Suite 2200
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94104
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/034,205
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  MacKnight, Kamrin T.
;      REGISTRATION NUMBER:  38,230
;      REFERENCE/DOCKET NUMBER:  FORS-03268
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 705-8410
;      TELEFAX:  (415) 397-8338
;  INFORMATION FOR SEQ ID NO:  50:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "DNA"
US-09-034-205-50

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2095 GCTCTCTGG 2103
             |||||||||
Db         10 GCTCTCTGG 2


RESULT 29
US-08-934-097A-50/c
; Sequence 50, Application US/08934097A
; Patent No. 6210880
;  GENERAL INFORMATION:
;    APPLICANT:  Lyamichev, Victor I.
;    APPLICANT:  Brow, Mary Ann D.
;    APPLICANT:  Fors, Lance
;    APPLICANT:  Neri, Bruce P.
;    TITLE OF INVENTION:  Polymorphism Analysis By Nucleic Acid
;    TITLE OF INVENTION:  Structure Probing With Structure-Bridging
;    TITLE OF INVENTION:  Oligonucleotides.
;    NUMBER OF SEQUENCES:  51
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MEDLEN & CARROLL, LLP
;      STREET:  220 Montgomery Street, Suite 2200
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94104
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
```

```
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/934,097A
;       FILING DATE:
;       CLASSIFICATION:  435
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  MacKnight, Kamrin T.
;       REGISTRATION NUMBER:  38,230
;       REFERENCE/DOCKET NUMBER:  FORS-02980
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (415) 705-8410
;       TELEFAX:  (415) 397-8338
;   INFORMATION FOR SEQ ID NO:  50:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  10 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid
;       DESCRIPTION:  /desc = "DNA"
US-08-934-097A-50

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2095 GCTCTCTGG 2103
              |||||||||
Db         10 GCTCTCTGG 2


RESULT 30
US-09-677-218B-50/c
; Sequence 50, Application US/09677218B
; Patent No. 6355437
;   GENERAL INFORMATION:
;       APPLICANT: Lyamichev, Victor I.
;                  Brow, Mary Ann D.
;                  Fors, Lance
;                  Neri, Bruce P.
;       TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING
;                           STRUCTURE-BRIDGING OLIGONUCLEOTIDES
;       NUMBER OF SEQUENCES: 68
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: MEDLEN & CARROLL, LLP
;            STREET: 220 Montgomery Street, Suite 2200
;            CITY: San Francisco
;            STATE: CA
;            COUNTRY: USA
;            ZIP: 94104
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/677,218B
;            FILING DATE: 02-Oct-2000
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/034,205
;            FILING DATE: <Unknown>
;       ATTORNEY/AGENT INFORMATION:
;            NAME: MacKnight, Kamrin T.
;            REGISTRATION NUMBER: 38,230
;            REFERENCE/DOCKET NUMBER: FORS-03268
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 705-8410
;            TELEFAX: (415) 397-8338
;   INFORMATION FOR SEQ ID NO: 50:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 10 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: other nucleic acid
;            DESCRIPTION: /desc = "DNA"
;       SEQUENCE DESCRIPTION: SEQ ID NO: 50:
US-09-677-218B-50

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2095 GCTCTCTGG 2103
              |||||||||
Db         10 GCTCTCTGG 2


RESULT 31
US-09-677-192-50/c
; Sequence 50, Application US/09677192
; Patent No. 6358691
; GENERAL INFORMATION:
;  APPLICANT:  Lyamichev, Victor I.
;  APPLICANT:  Brow, Mary Ann D.
;  APPLICANT:  Fors, Lance
;  APPLICANT:  Neri, Bruce P.
;  TITLE OF INVENTION:  TARGET-DEPENDENT REACTIONS USING STRUCTURE-BRIDGING
;  TITLE OF INVENTION:  OLIGONUCLEOTIDES
;  FILE REFERENCE:  FORS-04708
;  CURRENT APPLICATION NUMBER: US/09/677,192
;  CURRENT FILING DATE:  2000-10-02
;  PRIOR APPLICATION NUMBER:  09/034,205
;  PRIOR FILING DATE:  1998-03-03
;  NUMBER OF SEQ ID NOS:  68
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 50
;   LENGTH: 10
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Synthetic
US-09-677-192-50

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2095 GCTCTCTGG 2103
              |||||||||
Db         10 GCTCTCTGG 2


RESULT 32
US-09-255-899-4
; Sequence 4, Application US/09255899
; Patent No. 6368863
;   GENERAL INFORMATION:
;       APPLICANT: Ecker et al.
;       TITLE OF INVENTION: Reagents And Methods For Modulating Gene
;                           Expression Through RNA Mimicry
;       NUMBER OF SEQUENCES: 17
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6368863ris LLP
;            STREET: One Liberty Place - 46th Floor
;            CITY: Philadelphia
;            STATE: PA
;            COUNTRY: U.S.A.
;            ZIP: 19103
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
```

```
;             SOFTWARE: WordPerfect 6.1
;          CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/255,899
;             FILING DATE: 23-Feb-1999
;             CLASSIFICATION: <Unknown>
;          PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/461,418
;             FILING DATE: <Unknown>
;          ATTORNEY/AGENT INFORMATION:
;             NAME: Paul K. Legaard
;             REGISTRATION NUMBER: 38,534
;             REFERENCE/DOCKET NUMBER: ISIS-1998
;          TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 215-568-3100
;             TELEFAX: 215-568-3439
;    INFORMATION FOR SEQ ID NO: 4:
;          SEQUENCE CHARACTERISTICS:
;             LENGTH: 10 bases
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;          SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-255-899-4

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   66.7%;  Pred. No. 17;
  Matches    6;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2095 GCTCTCTGG 2103
              ||:|:|:||
Db          1 GCUCUCUGG 9


RESULT 33
US-09-402-618B-50/c
; Sequence 50, Application US/09402618B
; Patent No. 6709815
; GENERAL INFORMATION:
;  APPLICANT: Dong, Fang
;  APPLICANT:  Lyamichev, Victor
;  APPLICANT:  Prudent, James
;  APPLICANT:  Fors, Lance
;  APPLICANT:  Neri, Bruce
;  APPLICANT:  Brow, Mary Ann
;  APPLICANT:  Anderson, Todd
;  APPLICANT:  Dahlberg, James
;  TITLE OF INVENTION: Target-Dependent Reactions Using Structure-Bridging Oligonucleoti
;  FILE REFERENCE: FORS-04012
;  CURRENT APPLICATION NUMBER: US/09/402,618B
;  CURRENT FILING DATE:  2000-07-18
;  PRIOR APPLICATION NUMBER: PCT/US98/03194
;  PRIOR FILING DATE: 1998-05-05
;  NUMBER OF SEQ ID NOS: 128
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 50
;   LENGTH: 10
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-09-402-618B-50

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2095 GCTCTCTGG 2103
              |||||||||
Db         10 GCTCTCTGG 2


RESULT 34
US-09-825-574-50/c
; Sequence 50, Application US/09825574
; Patent No. 6709819
;  GENERAL INFORMATION:
;       APPLICANT: Lyamichev, Victor I.
;                  Brow, Mary Ann D.
;                  Fors, Lance
;                  Neri, Bruce P.
;       TITLE OF INVENTION: Polymorphism Analysis By Nucleic Acid
;                           Structure Probing With Structure-Bridging
;                           Oligonucleotides.
;       NUMBER OF SEQUENCES: 51
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: MEDLEN & CARROLL, LLP
;            STREET: 220 Montgomery Street, Suite 2200
;            CITY: San Francisco
;            STATE: CA
;            COUNTRY: USA
;            ZIP: 94104
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/825,574
;            FILING DATE: 03-Apr-2001
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/934,097
;            FILING DATE: <Unknown>
;       ATTORNEY/AGENT INFORMATION:
;            NAME: MacKnight, Kamrin T.
;            REGISTRATION NUMBER: 38,230
;            REFERENCE/DOCKET NUMBER: FORS-02980
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 705-8410
;            TELEFAX: (415) 397-8338
;   INFORMATION FOR SEQ ID NO: 50:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 10 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: other nucleic acid
;            DESCRIPTION: /desc = "DNA"
;       SEQUENCE DESCRIPTION: SEQ ID NO: 50:
US-09-825-574-50

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2095 GCTCTCTGG 2103
              |||||||||
Db         10 GCTCTCTGG 2


RESULT 35
PCT-US91-01822A-4
; Sequence 4, Application PC/TUS9101822A
;  GENERAL INFORMATION:
;    APPLICANT:  Ecker et al.
;    TITLE OF INVENTION:  REAGENTS AND METHODS FOR MODULATING
;    TITLE OF INVENTION:  GENE EXPRESSION THROUGH RNA MIMICRY
;    NUMBER OF SEQUENCES:  5
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz
;      ADDRESSEE:  Mackiewicz & Norris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
```

```
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;       COMPUTER:  IBM PS/2
;       OPERATING SYSTEM:  PC-DOS
;       SOFTWARE:  WORDPERFECT 5.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/US91/01822A
;       FILING DATE:  19910319
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  497,090
;       FILING DATE:  March 21, 1990
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Jane Massey Licata
;       REGISTRATION NUMBER:  32,257
;       REFERENCE/DOCKET NUMBER:  ISIS-0109
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (215) 568-3100
;       TELEFAX:  (215) 568-3439
;   INFORMATION FOR SEQ ID NO:  4:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  10
;       TYPE:  NUCLEIC ACID
;       STRANDEDNESS:  single
;       TOPOLOGY:  unknown
PCT-US91-01822A-4

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   66.7%;  Pred. No. 17;
  Matches    6;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2095 GCTCTCTGG 2103
             ||:|:|:||
Db          1 GCUCUCUGG 9


RESULT 36
PCT-US91-02628-4
; Sequence 4, Application PC/TUS9102628
;  GENERAL INFORMATION:
;     APPLICANT:  Ecker et al.
;     TITLE OF INVENTION:  REAGENTS AND METHODS FOR MODULATING
;     TITLE OF INVENTION:  GENE EXPRESSION THROUGH RNA MIMICRY
;     NUMBER OF SEQUENCES:  5
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Woodcock Washburn Kurtz
;       ADDRESSEE:  Mackiewicz & Norris
;       STREET:  One Liberty Place - 46th Floor
;       CITY:  Philadelphia
;       STATE:  PA
;       COUNTRY:  USA
;       ZIP:  19103
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;       COMPUTER:  IBM PS/2
;       OPERATING SYSTEM:  PC-DOS
;       SOFTWARE:  WORDPERFECT 5.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/US91/02628
;       FILING DATE:  19910417
;       CLASSIFICATION:  536
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  497,090
;       FILING DATE:  March 21, 1990
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Jane Massey Licata
;       REGISTRATION NUMBER:  32,257
;       REFERENCE/DOCKET NUMBER:  ISIS-0109
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (215) 568-3439
;       TELEFAX:  (215) 568-3439
;   INFORMATION FOR SEQ ID NO:  4:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  10
;       TYPE:  NUCLEIC ACID
;       STRANDEDNESS:  single
;       TOPOLOGY:  unknown
PCT-US91-02628-4

  Query Match             18.0%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   66.7%;  Pred. No. 17;
  Matches    6;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2095 GCTCTCTGG 2103
             ||:|:|:||
Db          1 GCUCUCUGG 9


RESULT 37
US-08-205-507-10
; Sequence 10, Application US/08205507
; Patent No. 5543507
;  GENERAL INFORMATION:
;     APPLICANT:  Phillip Dan Cook, Muthiah Manoharan, and Thomas          W.
;     APPLICANT:  Bruice
;     TITLE OF INVENTION:  Covalently Cross-Linked
;     TITLE OF INVENTION:  Oligonucleotides
;     NUMBER OF SEQUENCES:  17
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz & No. 5543507ris
;       STREET:  One Liberty Place - 46th Floor
;       CITY:  Philadelphia
;       STATE:  PA
;       COUNTRY:  USA
;       ZIP:  19103
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;       COMPUTER:  IBM PS/2
;       OPERATING SYSTEM:  PC-DOS
;       SOFTWARE:  WORDPERFECT 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/205,507
;       FILING DATE:  Herewith
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/US93/02059
;       FILING DATE:  March 5, 1993
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Joseph Lucci
;       REGISTRATION NUMBER:  33,307
;       REFERENCE/DOCKET NUMBER:  ISIS-1304
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (215) 568-3100
;       TELEFAX:  (215) 568-3439
;   INFORMATION FOR SEQ ID NO:  10:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  10
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     ANTI-SENSE:  no
US-08-205-507-10

  Query Match             16.8%;  Score 8.4;  DB 1;  Length 10;
  Best Local Similarity   60.0%;  Pred. No. 22;
  Matches    6;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2096 CTCTCTGGGC 2105
             |:|:|:|| |
Db          1 CUCUCUGGUC 10


RESULT 38
US-08-308-894-6
; Sequence 6, Application US/08308894
; Patent No. 5571672
```

```
;  GENERAL INFORMATION:
;    APPLICANT:  Slavicek, James M.
;    APPLICANT:  Garner, Karen J.
;    APPLICANT:  Schreiber, David E.
;    TITLE OF INVENTION:  GYPSY MOTH GENOTYPE ASSAY
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  USDA - Forest Products Laboratory
;      STREET:  One Gifford Pinchot Drive
;      CITY:  Madison
;      STATE:  WI
;      COUNTRY:  U.S.A.
;      ZIP:  53705-2398
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/308,894
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stockhausen, Janet I.
;      REGISTRATION NUMBER:  34,256
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 231-9502
;      TELEFAX:  (608) 231-9508
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  oligonucleotide
US-08-308-894-6

  Query Match             16.8%;  Score 8.4;  DB 1;  Length 10;
  Best Local Similarity   90.0%;  Pred. No. 22;
  Matches    9;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2073 GAGCCATCCA 2082
              ||||| ||||
Db          1 GAGCCCTCCA 10


RESULT 39
US-08-808-474A-3/c
; Sequence 3, Application US/08808474A
; Patent No. 5856103
;  GENERAL INFORMATION:
;    APPLICANT:  Gray, Donald M.
;    APPLICANT:  Clark, Chris L.
;    TITLE OF INVENTION:  METHOD FOR SELECTIVELY RANKING SEQUENCES
;    TITLE OF INVENTION:  FOR ANTISENSE TARGETING
;    NUMBER OF SEQUENCES:  37
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Locke Purnell Rain Harrell
;      STREET:  2200 Ross Avenue, Suite 2200
;      CITY:  Dallas
;      STATE:  Texas
;      COUNTRY:  USA
;      ZIP:  75201-6776
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/808,474A
;      FILING DATE:  03-MAR-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Mayfield, Denise L.
;      REGISTRATION NUMBER:  33,732
;      REFERENCE/DOCKET NUMBER:  UTDAL:001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (214) 740-8000
;      TELEFAX:  (214) 740-8800
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-808-474A-3

  Query Match             16.8%;  Score 8.4;  DB 1;  Length 10;
  Best Local Similarity   90.0%;  Pred. No. 22;
  Matches    9;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2096 CTCTCTGGGC 2105
              ||||| ||||
Db         10 CTCTCCGGGC 1


RESULT 40
US-08-388-353-442
; Sequence 442, Application US/08388353
; Patent No. 6010895
;  GENERAL INFORMATION:
;    APPLICANT:  Deacon, Nicholas J.
;    APPLICANT:  Learmont, Jennifer C.
;    APPLICANT:  McPhee, Dale A.
;    APPLICANT:  Crowe, Suzanne
;    APPLICANT:  Cooper, David
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  800
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/388,353
;      FILING DATE:  14-FEB-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  9606
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  442:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-388-353-442

  Query Match             16.8%;  Score 8.4;  DB 1;  Length 10;
  Best Local Similarity   90.0%;  Pred. No. 22;
  Matches    9;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2069 ACTTGAGCCA 2078
              | ||||||||
```

```
Db          1 AGTTGAGCCA 10


RESULT 41
US-08-388-353-585/c
; Sequence 585, Application US/08388353
; Patent No. 6010895
;  GENERAL INFORMATION:
;    APPLICANT:  Deacon, Nicholas J.
;    APPLICANT:  Learmont, Jennifer C.
;    APPLICANT:  McPhee, Dale A.
;    APPLICANT:  Crowe, Suzanne
;    APPLICANT:  Cooper, David
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  800
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/388,353
;      FILING DATE:  14-FEB-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  9606
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  585:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-388-353-585

  Query Match           16.8%;  Score 8.4;  DB 1;  Length 10;
  Best Local Similarity   90.0%;  Pred. No. 22;
  Matches    9;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2094 AGCTCTCTGG 2103
             ||||||| ||
Db         10 AGCTCTCGGG 1


RESULT 42
US-08-488-551B-442
; Sequence 442, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  442:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-442

  Query Match           16.8%;  Score 8.4;  DB 1;  Length 10;
  Best Local Similarity   90.0%;  Pred. No. 22;
  Matches    9;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2069 ACTTGAGCCA 2078
              | ||||||||
Db          1 AGTTGAGCCA 10


RESULT 43
US-08-488-551B-585/c
; Sequence 585, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
```

```
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  585:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-585

  Query Match            16.8%;  Score 8.4;  DB 1;  Length 10;
  Best Local Similarity   90.0%;  Pred. No. 22;
  Matches    9;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2094 AGCTCTCTGG 2103
             ||||||| ||
Db         10 AGCTCTCGGG 1


RESULT 44
US-09-508-753B-166
; Sequence 166, Application US/09508753B
; Patent No. 6544736
; GENERAL INFORMATION:
;  APPLICANT: Akira SHIMAMOTO
;  APPLICANT:  Yasuhiro FURUICHI
;  APPLICANT:  Yuko SHIBATA
;  APPLICANT:  Hiroko FUNAKI
;  APPLICANT:  Eiji OHARA
;  APPLICANT:  Masanori WATAHIKI
;  TITLE OF INVENTION: Method for Synthesizing cDNA from mRNA sample
;  FILE REFERENCE: 00162/HG
;  CURRENT APPLICATION NUMBER: US/09/508,753B
;  CURRENT FILING DATE:  2000-06-16
;  PRIOR APPLICATION NUMBER: JP 9/270324
;  PRIOR FILING DATE: 1997-09-18
;  NUMBER OF SEQ ID NOS: 472
; SEQ ID NO 166
;   LENGTH: 10
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-508-753B-166

  Query Match            16.8%;  Score 8.4;  DB 1;  Length 10;
  Best Local Similarity   90.0%;  Pred. No. 22;
  Matches    9;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2072 TGAGCCATCC 2081
             | ||||||||
Db          1 TAAGCCATCC 10


RESULT 45
US-09-769-482-16/c
; Sequence 16, Application US/09769482
; Patent No. 6566130
; GENERAL INFORMATION:
;  APPLICANT: SRIVASTAVA, SHIV
;  APPLICANT:  MOUL, JUDD W.
;  APPLICANT:  XU, LINDA L.
;  APPLICANT:  SEGAWA, TAKEHIKO
;  TITLE OF INVENTION: PROSTATE-SPECIFIC ANDROGEN-SIGNALING-ASSOCIATED
;  TITLE OF INVENTION:  POYNUCLEOTIDE ARRAY
;  FILE REFERENCE: 04995.0057-00000
;  CURRENT APPLICATION NUMBER: US/09/769,482
;  CURRENT FILING DATE:  2001-01-26
;  PRIOR APPLICATION NUMBER: 60/178,772
;  PRIOR FILING DATE: 2000-01-28
;  PRIOR APPLICATION NUMBER: 60/179,045
;  PRIOR FILING DATE: 2000-01-31
;  NUMBER OF SEQ ID NOS: 67
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 10
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-09-769-482-16

  Query Match            16.8%;  Score 8.4;  DB 1;  Length 10;
  Best Local Similarity   90.0%;  Pred. No. 22;
  Matches    9;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2070 CTTGAGCCAT 2079
             |||||| |||
Db         10 CTTGAGTCAT 1


RESULT 46
US-09-822-250A-21/c
; Sequence 21, Application US/09822250A
; Patent No. 6706477
; GENERAL INFORMATION:
;  APPLICANT: Zauderer, Maurice
;  TITLE OF INVENTION: Methods for Producing Polynucleotide Libraries in Vaccinia Virus
;  FILE REFERENCE: 1821.0010001
;  CURRENT APPLICATION NUMBER: US/09/822,250A
;  CURRENT FILING DATE:  2001-04-02
;  PRIOR APPLICATION NUMBER: US 08/935,377
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 38
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 21
;   LENGTH: 10
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: MR_14 primer
US-09-822-250A-21

  Query Match            16.8%;  Score 8.4;  DB 1;  Length 10;
  Best Local Similarity   90.0%;  Pred. No. 22;
  Matches    9;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2067 AGACTTGAGC 2076
             |||||||| |
Db         10 AGACTTGATC 1


Search completed: November  8, 2004, 15:26:24
Job time : 1 secs
```

OM nucleic - nucleic search, using sw model

Run on: November 8, 2004, 15:24:45 ; Search time 0.001 Seconds
(without alignments)
144.800 Million cell updates/sec

Title: us-10-655-847-18
Perfect score: 50
Sequence: 1 ttcagagcaaaagacttgag.....aaacactaagctctctgggc 50

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 106 seqs, 1448 residues

Total number of hits satisfying chosen parameters: 212

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 106 summaries

Database : rngdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	20	40.0	20	1	ADG86982	Human PPAR antisen
c	2	20	40.0	20	1	ADG86835	Human PPAR antisen
	3	20	40.0	20	1	ADG86981	Human PPAR antisen
	4	20	40.0	20	1	ADG86983	Human PPAR antisen
c	5	20	40.0	20	1	ADG86836	Human PPAR antisen
c	6	20	40.0	20	1	ADG86837	Human PPAR antisen
	7	20	40.0	20	1	ADL34920	Human PPAR-delta t
c	8	20	40.0	20	1	ADL34774	Antisense oligonuc
c	9	20	40.0	20	1	ADL34773	Antisense oligonuc
	10	20	40.0	20	1	ADL34921	Human PPAR-delta t
	11	20	40.0	20	1	ADL34919	Human PPAR-delta t
c	12	20	40.0	20	1	ADL34775	Antisense oligonuc
c	13	14.4	28.8	18	1	ABZ10726	Haematopoietic cel
c	14	14.4	28.8	18	1	ADB54738	Hybridisation olig
c	15	14.4	28.8	18	1	ADC70291	Primer oligo used
c	16	14.4	28.8	18	1	ADE84512	Human lymphoid cel
	17	13.8	27.6	17	1	AAX75280	Mouse flt-1 VEGF r
c	18	12.4	24.8	15	1	AAF47731	IGFBP3 oligonucleo
c	19	12.4	24.8	15	1	AAF47730	IGFBP3 oligonucleo
c	20	12	24.0	15	1	AAT52513	Mouse ICAM hammerh
	21	11.4	22.8	13	1	ABF44787	Oligonucleotide SE
c	22	11.4	22.8	13	1	ABC05028	Oligonucleotide SE
	23	11.4	22.8	13	1	ABC05029	Oligonucleotide SE
c	24	11.4	22.8	13	1	ABF48836	Oligonucleotide SE
c	25	11.4	22.8	13	1	ABF44786	Oligonucleotide SE
	26	11.4	22.8	13	1	ABF48837	Oligonucleotide SE
c	27	11	22.0	13	1	ABF26976	Oligonucleotide SE
	28	11	22.0	13	1	ABF26977	Oligonucleotide SE
c	29	11	22.0	13	1	ABF85994	Oligonucleotide SE
c	30	11	22.0	13	1	ABF87456	Oligonucleotide SE
	31	11	22.0	13	1	ABF85995	Oligonucleotide SE
	32	11	22.0	13	1	ABF87457	Oligonucleotide SE
	33	10.4	20.8	12	1	ABI58987	Oligonucleotide pr
c	34	10.4	20.8	12	1	ABH75972	Oligonucleotide pr
	35	10.4	20.8	12	1	ABI44086	Oligonucleotide pr
c	36	10.4	20.8	12	1	ABI74566	Oligonucleotide pr
	37	10.4	20.8	12	1	ABI73012	Oligonucleotide pr
	38	10.4	20.8	12	1	ABI40361	Oligonucleotide pr
	39	10.4	20.8	12	1	ABI54654	Oligonucleotide pr
	40	10.4	20.8	12	1	ABI61429	Oligonucleotide pr
c	41	10.4	20.8	12	1	ABI28939	Oligonucleotide pr
c	42	10.4	20.8	12	1	ABI68635	Oligonucleotide pr
	43	10.4	20.8	12	1	ABH86185	Oligonucleotide pr
c	44	10.4	20.8	12	1	ABI77309	Oligonucleotide pr
c	45	10.4	20.8	12	1	ABH88737	Oligonucleotide pr
c	46	10.4	20.8	12	1	ABI78875	Oligonucleotide pr
	47	10.4	20.8	12	1	ABH69603	Oligonucleotide pr
c	48	10.4	20.8	12	1	ABH82641	Oligonucleotide pr
	49	10.4	20.8	12	1	ABI57188	Oligonucleotide pr
c	50	10.4	20.8	12	1	ABI27995	Oligonucleotide pr
c	51	10.4	20.8	12	1	ABI44646	Oligonucleotide pr
c	52	10.4	20.8	12	1	ABI20258	Oligonucleotide pr
	53	10.4	20.8	12	1	ABH89528	Oligonucleotide pr
c	54	10.4	20.8	12	1	ABI58394	Oligonucleotide pr
	55	10.4	20.8	12	1	ABI65055	Oligonucleotide pr
	56	10.4	20.8	13	1	AAV06890	One from an array
	57	10.4	20.8	13	1	ABC52017	Oligonucleotide SE
c	58	10.4	20.8	13	1	ABC52018	Oligonucleotide SE
	59	10.4	20.8	13	1	ABC15655	Oligonucleotide SE
	60	10.4	20.8	13	1	ABH12189	Oligonucleotide SE
c	61	10.4	20.8	13	1	ABC34878	Oligonucleotide SE
	62	10.4	20.8	13	1	ABF16561	Oligonucleotide SE
	63	10.4	20.8	13	1	ABF75305	Oligonucleotide SE
c	64	10.4	20.8	13	1	ABF30114	Oligonucleotide SE
	65	10.4	20.8	13	1	ABF30115	Oligonucleotide SE
c	66	10.4	20.8	13	1	ABF44362	Oligonucleotide SE
c	67	10.4	20.8	13	1	ABF61404	Oligonucleotide SE
	68	10.4	20.8	13	1	ABC52019	Oligonucleotide SE
	69	10.4	20.8	13	1	ABC34879	Oligonucleotide SE
c	70	10.4	20.8	13	1	ABC61946	Oligonucleotide SE
c	71	10.4	20.8	13	1	ABF26456	Oligonucleotide SE
	72	10.4	20.8	13	1	ABF44363	Oligonucleotide SE
	73	10.4	20.8	13	1	ABH56791	Oligonucleotide SE
c	74	10.4	20.8	13	1	ABC52016	Oligonucleotide SE
	75	10.4	20.8	13	1	ABH42205	Oligonucleotide SE
c	76	10.4	20.8	13	1	ABC15654	Oligonucleotide SE
c	77	10.4	20.8	13	1	ABH41536	Oligonucleotide SE
c	78	10.4	20.8	13	1	ABH56790	Oligonucleotide SE
	79	10.4	20.8	13	1	ABF26457	Oligonucleotide SE
	80	10.4	20.8	13	1	ABC95309	Oligonucleotide SE
	81	10.4	20.8	13	1	ABF25417	Oligonucleotide SE
	82	10.4	20.8	13	1	ABC90389	Oligonucleotide SE
c	83	10.4	20.8	13	1	ABC95308	Oligonucleotide SE
	84	10.4	20.8	13	1	ABC05733	Oligonucleotide SE
c	85	10.4	20.8	13	1	ABF75304	Oligonucleotide SE
c	86	10.4	20.8	13	1	ABH42204	Oligonucleotide SE
	87	10.4	20.8	13	1	ABF03883	Oligonucleotide SE
c	88	10.4	20.8	13	1	ABC05732	Oligonucleotide SE
	89	10.4	20.8	13	1	ABC61947	Oligonucleotide SE
c	90	10.4	20.8	13	1	ABH12188	Oligonucleotide SE
c	91	10.4	20.8	13	1	ABF03882	Oligonucleotide SE
	92	10.4	20.8	13	1	ABF61405	Oligonucleotide SE
c	93	10.4	20.8	13	1	ABC90388	Oligonucleotide SE
c	94	10.4	20.8	13	1	ABF16560	Oligonucleotide SE
c	95	10.4	20.8	13	1	ABF25416	Oligonucleotide SE
	96	10.4	20.8	13	1	ABH41537	Oligonucleotide SE
c	97	10	20.0	10	1	AAQ96819	HIV-1 NL4-3 nef ge
	98	10	20.0	10	1	AAQ97069	HIV-1 NL4-3 LTR nu
	99	10	20.0	10	1	AAZ82752	Metastatic breast
c	100	10	20.0	11	1	ABV63489	Human skin EST 127
c	101	10	20.0	11	1	ABV65107	Human skin EST 289
c	102	10	20.0	11	1	ABV70910	Human skin EST 869
	103	10	20.0	11	1	ADK13992	Human methyl-CpG-b
c	104	10	20.0	11	1	ADQ35744	Human hair-bearing
c	105	10	20.0	12	1	ABI67934	Oligonucleotide pr
c	106	10	20.0	12	1	ADF78682	Chromosomal abnorm

ALIGNMENTS

```
RESULT 1
ADG86982
ID   ADG86982 standard; cDNA; 20 BP.
XX
AC   ADG86982;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Human PPAR antisense oligonucleotoide target sequence #44.
XX
KW   Human; ss; PPAR delta; peroxisome proliferative activated receptor delta;
KW   antisense gene therapy; cytostatic; osteopathic; antidiabetic; cancer;
KW   osteoporosis; diabetes; endocrine disorder.
XX
OS   Homo sapiens.
XX
PN   US2003224514-A1.
XX
PD   04-DEC-2003.
XX
PF   31-MAY-2002; 2002US-00160807.
XX
PR   31-MAY-2002; 2002US-00160807.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Gaarde W,  Freier SM,  Watt AT;
XX
DR   WPI; 2004-022078/02.
XX
PT   New antisense oligonucleotides of 8-80 nucleobases, useful for treating
PT   cancer, diabetes, osteoporosis or various endocrine disorders.
XX
PS   Example 16; SEQ ID NO 218; 155pp; English.
XX
CC   The invention relates to an antisense oligonucleotide comprising 8-80
CC   nucleobases in length targeted to the coding region of a nucleic acid
CC   molecule encoding PPAR-delta (peroxisome proliferative activated receptor
CC   delta), where the antisense compound inhibits the expression of the PPAR-
CC   delta and has any of the 66 sequences of 20 amino acids fully defined in
CC   the specification. Also included are a compound of 8-80 nucleobases in
CC   length that specifically hybridises with at least an 8-nucleobase portion
CC   of a preferred target region on a nucleic acid molecule encoding PPAR-
CC   delta and a composition comprising the antisense oligonucleotide and a
CC   carrier. The antisense oligonucleotide comprises at least one modified
CC   internucleoside linkage (preferably a phosphorothioate linkage), at least
CC   one sugar moiety (preferably 2'-O-methoxyethyl moiety) and at least one
CC   modified nucleobase (which is a 5-methyl cytosine). The antisense
CC   compounds are useful for treating cancer, osteoporosis, diabetes or
CC   various endocrine disorders. The Human PPAR delta gene is located on
CC   chromosome 6p21. The present sequence is a human PPAR delta cDNA target
CC   sequence for the antisense oligonucleotides of the invention.
XX
SQ   Sequence 20 BP; 9 A; 6 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match            40.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity  100.0%;  Pred. No. 4.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2073 GAGCCATCCAAAGAAACACT 2092
             ||||||||||||||||||||
Db          1 GAGCCATCCAAAGAAACACT 20


RESULT 2
ADG86835/c
ID   ADG86835 standard; DNA; 20 BP.
XX
AC   ADG86835;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Human PPAR antisense oligonuclotide ISIS 136914.
XX
KW   Human; ss; PPAR delta; peroxisome proliferative activated receptor delta;
KW   antisense gene therapy; cytostatic; osteopathic; antidiabetic; cancer;
KW   osteoporosis; diabetes; endocrine disorder.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate linkages and all cytidines are 5
FT                    -methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl residue"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl residue"
XX
PN   US2003224514-A1.
XX
PD   04-DEC-2003.
XX
PF   31-MAY-2002; 2002US-00160807.
XX
PR   31-MAY-2002; 2002US-00160807.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Gaarde W,  Freier SM,  Watt AT;
XX
DR   WPI; 2004-022078/02.
XX
PT   New antisense oligonucleotides of 8-80 nucleobases, useful for treating
PT   cancer, diabetes, osteoporosis or various endocrine disorders.
XX
PS   Claim 1; SEQ ID NO 71; 155pp; English.
XX
CC   The invention relates to an antisense oligonucleotide comprising 8-80
CC   nucleobases in length targeted to the coding region of a nucleic acid
CC   molecule encoding PPAR-delta (peroxisome proliferative activated receptor
CC   delta), where the antisense compound inhibits the expression of the PPAR-
CC   delta and has any of the 66 sequences of 20 amino acids fully defined in
CC   the specification. Also included are a compound of 8-80 nucleobases in
CC   length that specifically hybridises with at least an 8-nucleobase portion
CC   of a preferred target region on a nucleic acid molecule encoding PPAR-
CC   delta and a composition comprising the antisense oligonucleotide and a
CC   carrier. The antisense oligonucleotide comprises at least one modified
CC   internucleoside linkage (preferably a phosphorothioate linkage), at least
CC   one sugar moiety (preferably 2'-O-methoxyethyl moiety) and at least one
CC   modified nucleobase (which is a 5-methyl cytosine). The antisense
CC   compounds are useful for treating cancer, osteoporosis, diabetes or
CC   various endocrine disorders. The Human PPAR delta gene is located on
CC   chromosome 6p21. The present sequence is an antisense oligonucleotide of
CC   the invention targeting human PPAR delta.
XX
SQ   Sequence 20 BP; 4 A; 5 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match            40.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity  100.0%;  Pred. No. 4.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2056 TTCAGAGCAAAAGACTTGAG 2075
             ||||||||||||||||||||
Db         20 TTCAGAGCAAAAGACTTGAG 1
```

```
RESULT 3
ADG86981
ID   ADG86981 standard; cDNA; 20 BP.
XX
AC   ADG86981;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Human PPAR antisense oligonucleotoide target sequence #43.
XX
KW   Human; ss; PPAR delta; peroxisome proliferative activated receptor delta;
KW   antisense gene therapy; cytostatic; osteopathic; antidiabetic; cancer;
KW   osteoporosis; diabetes; endocrine disorder.
XX
OS   Homo sapiens.
XX
PN   US2003224514-A1.
XX
PD   04-DEC-2003.
XX
PF   31-MAY-2002; 2002US-00160807.
XX
PR   31-MAY-2002; 2002US-00160807.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Gaarde W,  Freier SM,  Watt AT;
XX
DR   WPI; 2004-022078/02.
XX
PT   New antisense oligonucleotides of 8-80 nucleobases, useful for treating
PT   cancer, diabetes, osteoporosis or various endocrine disorders.
XX
PS   Example 16; SEQ ID NO 217; 155pp; English.
XX
CC   The invention relates to an antisense oligonucleotide comprising 8-80
CC   nucleobases in length targeted to the coding region of a nucleic acid
CC   molecule encoding PPAR-delta (peroxisome proliferative activated receptor
CC   delta), where the antisense compound inhibits the expression of the PPAR-
CC   delta and has any of the 66 sequences of 20 amino acids fully defined in
CC   the specification. Also included are a compound of 8-80 nucleobases in
CC   length that specifically hybridises with at least an 8-nucleobase portion
CC   of a preferred target region on a nucleic acid molecule encoding PPAR-
CC   delta and a composition comprising the antisense oligonucleotide and a
CC   carrier. The antisense oligonucleotide comprises at least one modified
CC   internucleoside linkage (preferably a phosphorothioate linkage), at least
CC   one sugar moiety (preferably 2'-O-methoxyethyl moiety) and at least one
CC   modified nucleobase (which is a 5-methyl cytosine). The antisense
CC   compounds are useful for treating cancer, osteoporosis, diabetes or
CC   various endocrine disorders. The Human PPAR delta gene is located on
CC   chromosome 6p21. The present sequence is a human PPAR delta cDNA target
CC   sequence for the antisense oligonucleotides of the invention.
XX
SQ   Sequence 20 BP; 8 A; 3 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             40.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2056 TTCAGAGCAAAAGACTTGAG 2075
              ||||||||||||||||||||
Db          1 TTCAGAGCAAAAGACTTGAG 20


RESULT 4
ADG86983
ID   ADG86983 standard; cDNA; 20 BP.
XX
AC   ADG86983;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Human PPAR antisense oligonucleotoide target sequence #45.
XX
KW   Human; ss; PPAR delta; peroxisome proliferative activated receptor delta;
KW   antisense gene therapy; cytostatic; osteopathic; antidiabetic; cancer;
KW   osteoporosis; diabetes; endocrine disorder.
XX
OS   Homo sapiens.
XX
PN   US2003224514-A1.
XX
PD   04-DEC-2003.
XX
PF   31-MAY-2002; 2002US-00160807.
XX
PR   31-MAY-2002; 2002US-00160807.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Gaarde W,  Freier SM,  Watt AT;
XX
DR   WPI; 2004-022078/02.
XX
PT   New antisense oligonucleotides of 8-80 nucleobases, useful for treating
PT   cancer, diabetes, osteoporosis or various endocrine disorders.
XX
PS   Example 16; SEQ ID NO 219; 155pp; English.
XX
CC   The invention relates to an antisense oligonucleotide comprising 8-80
CC   nucleobases in length targeted to the coding region of a nucleic acid
CC   molecule encoding PPAR-delta (peroxisome proliferative activated receptor
CC   delta), where the antisense compound inhibits the expression of the PPAR-
CC   delta and has any of the 66 sequences of 20 amino acids fully defined in
CC   the specification. Also included are a compound of 8-80 nucleobases in
CC   length that specifically hybridises with at least an 8-nucleobase portion
CC   of a preferred target region on a nucleic acid molecule encoding PPAR-
CC   delta and a composition comprising the antisense oligonucleotide and a
CC   carrier. The antisense oligonucleotide comprises at least one modified
CC   internucleoside linkage (preferably a phosphorothioate linkage), at least
CC   one sugar moiety (preferably 2'-O-methoxyethyl moiety) and at least one
CC   modified nucleobase (which is a 5-methyl cytosine). The antisense
CC   compounds are useful for treating cancer, osteoporosis, diabetes or
CC   various endocrine disorders. The Human PPAR delta gene is located on
CC   chromosome 6p21. The present sequence is a human PPAR delta cDNA target
CC   sequence for the antisense oligonucleotides of the invention.
XX
SQ   Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             40.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAGCTCTCTGGGC 2105
              ||||||||||||||||||||
Db          1 AAACACTAAGCTCTCTGGGC 20


RESULT 5
ADG86836/c
ID   ADG86836 standard; DNA; 20 BP.
XX
AC   ADG86836;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Human PPAR antisense oligonuclotide ISIS 136915.
XX
KW   Human; ss; PPAR delta; peroxisome proliferative activated receptor delta;
KW   antisense gene therapy; cytostatic; osteopathic; antidiabetic; cancer;
KW   osteoporosis; diabetes; endocrine disorder.
XX
OS   Homo sapiens.
XX
```

```
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages and all cytidines are 5
FT                   -methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl residue"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl residue"
XX
PN   US2003224514-A1.
XX
PD   04-DEC-2003.
XX
PF   31-MAY-2002; 2002US-00160807.
XX
PR   31-MAY-2002; 2002US-00160807.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Gaarde W,  Freier SM,  Watt AT;
XX
DR   WPI; 2004-022078/02.
XX
PT   New antisense oligonucleotides of 8-80 nucleobases, useful for treating
PT   cancer, diabetes, osteoporosis or various endocrine disorders.
XX
PS   Claim 1; SEQ ID NO 72; 155pp; English.
XX
CC   The invention relates to an antisense oligonucleotide comprising 8-80
CC   nucleobases in length targeted to the coding region of a nucleic acid
CC   molecule encoding PPAR-delta (peroxisome proliferative activated receptor
CC   delta), where the antisense compound inhibits the expression of the PPAR-
CC   delta and has any of the 66 sequences of 20 amino acids fully defined in
CC   the specification. Also included are a compound of 8-80 nucleobases in
CC   length that specifically hybridises with at least an 8-nucleobase portion
CC   of a preferred target region on a nucleic acid molecule encoding PPAR-
CC   delta and a composition comprising the antisense oligonucleotide and a
CC   carrier. The antisense oligonucleotide comprises at least one modified
CC   internucleoside linkage (preferably a phosphorothioate linkage), at least
CC   one sugar moiety (preferably 2'-O-methoxyethyl moiety) and at least one
CC   modified nucleobase (which is a 5-methyl cytosine). The antisense
CC   compounds are useful for treating cancer, osteoporosis, diabetes or
CC   various endocrine disorders. The Human PPAR delta gene is located on
CC   chromosome 6p21. The present sequence is an antisense oligonucleotide of
CC   the invention targeting human PPAR delta.
XX
SQ   Sequence 20 BP; 2 A; 3 C; 6 G; 9 T; 0 U; 0 Other;

  Query Match             40.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2073 GAGCCATCCAAAGAAACACT 2092
              ||||||||||||||||||||
Db         20 GAGCCATCCAAAGAAACACT 1


RESULT 6
ADG86837/c
ID   ADG86837 standard; DNA; 20 BP.
XX
AC   ADG86837;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Human PPAR antisense oligonuclotide ISIS 136916.
XX
KW   Human; ss; PPAR delta; peroxisome proliferative activated receptor delta;
KW   antisense gene therapy; cytostatic; osteopathic; antidiabetic; cancer;
KW   osteoporosis; diabetes; endocrine disorder.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages and all cytidines are 5
FT                   -methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl residue"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl residue"
XX
PN   US2003224514-A1.
XX
PD   04-DEC-2003.
XX
PF   31-MAY-2002; 2002US-00160807.
XX
PR   31-MAY-2002; 2002US-00160807.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Gaarde W,  Freier SM,  Watt AT;
XX
DR   WPI; 2004-022078/02.
XX
PT   New antisense oligonucleotides of 8-80 nucleobases, useful for treating
PT   cancer, diabetes, osteoporosis or various endocrine disorders.
XX
PS   Claim 1; SEQ ID NO 73; 155pp; English.
XX
CC   The invention relates to an antisense oligonucleotide comprising 8-80
CC   nucleobases in length targeted to the coding region of a nucleic acid
CC   molecule encoding PPAR-delta (peroxisome proliferative activated receptor
CC   delta), where the antisense compound inhibits the expression of the PPAR-
CC   delta and has any of the 66 sequences of 20 amino acids fully defined in
CC   the specification. Also included are a compound of 8-80 nucleobases in
CC   length that specifically hybridises with at least an 8-nucleobase portion
CC   of a preferred target region on a nucleic acid molecule encoding PPAR-
CC   delta and a composition comprising the antisense oligonucleotide and a
CC   carrier. The antisense oligonucleotide comprises at least one modified
CC   internucleoside linkage (preferably a phosphorothioate linkage), at least
CC   one sugar moiety (preferably 2'-O-methoxyethyl moiety) and at least one
CC   modified nucleobase (which is a 5-methyl cytosine). The antisense
CC   compounds are useful for treating cancer, osteoporosis, diabetes or
CC   various endocrine disorders. The Human PPAR delta gene is located on
CC   chromosome 6p21. The present sequence is an antisense oligonucleotide of
CC   the invention targeting human PPAR delta.
XX
SQ   Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             40.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAGCTCTCTGGGC 2105
              ||||||||||||||||||||
Db         20 AAACACTAAGCTCTCTGGGC 1


RESULT 7
ADL34920
ID   ADL34920 standard; DNA; 20 BP.
XX
```

AC ADL34920;
XX
DT 17-JUN-2004 (first entry)
XX
DE Human PPAR-delta target site ID 50035.
XX
KW antisense; PPAR-delta; human; hybridisation; inhibitor;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW hyperproliferative disorder; cancer; cytostatic; gene therapy; ds.
XX
OS Homo sapiens.
XX
PN US2004063129-A1.
XX
PD 01-APR-2004.
XX
PF 05-SEP-2003; 2003US-00655847.
XX
PR 31-MAY-2002; 2002US-00160807.
XX
PA (GAAR/) GAARDE W.
PA (FREI/) FREIER S M.
PA (WATT/) WATT A T.
XX
PI Gaarde W, Freier SM, Watt AT;
XX
DR WPI; 2004-282460/26.
XX
PT New antisense oligonucleotide, having a sequence targeted to a nucleic
PT acid encoding PPAR-delta, useful for preparing a composition for treating
PT hyperproliferative disorder, e.g., cancer.
XX
PS Example 16; SEQ ID NO 218; 0pp; English.
XX
CC This invention describes novel antisense oligonucleotides targeted to a
CC nucleic acid encoding PPAR-delta, which specifically hybridise to and
CC inhibit expression of PPAR-delta. The oligonucleotide specifically
CC hybridises with at least an 8-nucleobase portion of an active site on the
CC nucleic acid molecule encoding the PPAR-delta and comprises at least one
CC modified internucleoside linkage, which is a phosphorothioate linkage, at
CC least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar
CC moiety or at least one modified nucleobase, which is a 5-methylcytosine.
CC The antisense oligonucleotides are useful for preparing a composition for
CC treating hyperproliferative disorders, e.g., cancer. The oligonucleotides
CC of the invention have cytostatic activity and can be used for gene
CC therapy.
XX
SQ Sequence 20 BP; 9 A; 6 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 40.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.6;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2073 GAGCCATCCAAAGAAACACT 2092
||||||||||||||||||||
Db 1 GAGCCATCCAAAGAAACACT 20

RESULT 8
ADL34774/c
ID ADL34774 standard; DNA; 20 BP.
XX
AC ADL34774;
XX
DT 17-JUN-2004 (first entry)
XX
DE Antisense oligonucleotide ISIS 136915.
XX
KW antisense; PPAR-delta; human; hybridisation; inhibitor;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW hyperproliferative disorder; cancer; cytostatic; gene therapy; ss;
KW primer.
XX
OS Synthetic.
XX
PN US2004063129-A1.
XX
PD 01-APR-2004.
XX
PF 05-SEP-2003; 2003US-00655847.
XX
PR 31-MAY-2002; 2002US-00160807.
XX
PA (GAAR/) GAARDE W.
PA (FREI/) FREIER S M.
PA (WATT/) WATT A T.
XX
PI Gaarde W, Freier SM, Watt AT;
XX
DR WPI; 2004-282460/26.
XX
PT New antisense oligonucleotide, having a sequence targeted to a nucleic
PT acid encoding PPAR-delta, useful for preparing a composition for treating
PT hyperproliferative disorder, e.g., cancer.
XX
PS Example 15; SEQ ID NO 72; 0pp; English.
XX
CC This invention describes novel antisense oligonucleotides targeted to a
CC nucleic acid encoding PPAR-delta, which specifically hybridise to and
CC inhibit expression of PPAR-delta. The oligonucleotide specifically
CC hybridises with at least an 8-nucleobase portion of an active site on the
CC nucleic acid molecule encoding the PPAR-delta and comprises at least one
CC modified internucleoside linkage, which is a phosphorothioate linkage, at
CC least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar
CC moiety or at least one modified nucleobase, which is a 5-methylcytosine.
CC The antisense oligonucleotides are useful for preparing a composition for
CC treating hyperproliferative disorders, e.g., cancer. The oligonucleotides
CC of the invention have cytostatic activity and can be used for gene
CC therapy.
XX
SQ Sequence 20 BP; 2 A; 3 C; 6 G; 9 T; 0 U; 0 Other;

Query Match 40.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.6;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2073 GAGCCATCCAAAGAAACACT 2092
||||||||||||||||||||
Db 20 GAGCCATCCAAAGAAACACT 1

RESULT 9
ADL34773/c
ID ADL34773 standard; DNA; 20 BP.
XX
AC ADL34773;
XX
DT 17-JUN-2004 (first entry)
XX
DE Antisense oligonucleotide ISIS 136914.
XX
KW antisense; PPAR-delta; human; hybridisation; inhibitor;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW hyperproliferative disorder; cancer; cytostatic; gene therapy; ss;
KW primer.
XX
OS Synthetic.
XX
PN US2004063129-A1.
XX
PD 01-APR-2004.
XX
PF 05-SEP-2003; 2003US-00655847.
XX
PR 31-MAY-2002; 2002US-00160807.
XX

```
PA   (GAAR/) GAARDE W.
PA   (FREI/) FREIER S M.
PA   (WATT/) WATT A T.
XX
PI   Gaarde W,  Freier SM,  Watt AT;
XX
DR   WPI; 2004-282460/26.
XX
PT   New antisense oligonucleotide, having a sequence targeted to a nucleic
PT   acid encoding PPAR-delta, useful for preparing a composition for treating
PT   hyperproliferative disorder, e.g., cancer.
XX
PS   Example 15; SEQ ID NO 71; 0pp; English.
XX
CC   This invention describes novel antisense oligonucleotides targeted to a
CC   nucleic acid encoding PPAR-delta, which specifically hybridise to and
CC   inhibit expression of PPAR-delta. The oligonucleotide specifically
CC   hybridises with at least an 8-nucleobase portion of an active site on the
CC   nucleic acid molecule encoding the PPAR-delta and comprises at least one
CC   modified internucleoside linkage, which is a phosphorothioate linkage, at
CC   least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar
CC   moiety or at least one modified nucleobase, which is a 5-methylcytosine.
CC   The antisense oligonucleotides are useful for preparing a composition for
CC   treating hyperproliferative disorders, e.g., cancer. The oligonucleotides
CC   of the invention have cytostatic activity and can be used for gene
CC   therapy.
XX
SQ   Sequence 20 BP; 4 A; 5 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             40.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2056 TTCAGAGCAAAAGACTTGAG 2075
              ||||||||||||||||||||
Db         20 TTCAGAGCAAAAGACTTGAG 1


RESULT 10
ADL34921
ID   ADL34921 standard; DNA; 20 BP.
XX
AC   ADL34921;
XX
DT   17-JUN-2004  (first entry)
XX
DE   Human PPAR-delta target site ID 50036.
XX
KW   antisense; PPAR-delta; human; hybridisation; inhibitor;
KW   phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW   hyperproliferative disorder; cancer; cytostatic; gene therapy; ds.
XX
OS   Homo sapiens.
XX
PN   US2004063129-A1.
XX
PD   01-APR-2004.
XX
PF   05-SEP-2003; 2003US-00655847.
XX
PR   31-MAY-2002; 2002US-00160807.
XX
PA   (GAAR/) GAARDE W.
PA   (FREI/) FREIER S M.
PA   (WATT/) WATT A T.
XX
PI   Gaarde W,  Freier SM,  Watt AT;
XX
DR   WPI; 2004-282460/26.
XX
PT   New antisense oligonucleotide, having a sequence targeted to a nucleic
PT   acid encoding PPAR-delta, useful for preparing a composition for treating
PT   hyperproliferative disorder, e.g., cancer.
XX
PS   Example 16; SEQ ID NO 219; 0pp; English.
XX
CC   This invention describes novel antisense oligonucleotides targeted to a
CC   nucleic acid encoding PPAR-delta, which specifically hybridise to and
CC   inhibit expression of PPAR-delta. The oligonucleotide specifically
CC   hybridises with at least an 8-nucleobase portion of an active site on the
CC   nucleic acid molecule encoding the PPAR-delta and comprises at least one
CC   modified internucleoside linkage, which is a phosphorothioate linkage, at
CC   least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar
CC   moiety or at least one modified nucleobase, which is a 5-methylcytosine.
CC   The antisense oligonucleotides are useful for preparing a composition for
CC   treating hyperproliferative disorders, e.g., cancer. The oligonucleotides
CC   of the invention have cytostatic activity and can be used for gene
CC   therapy.
XX
SQ   Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             40.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAGCTCTCTGGGC 2105
              ||||||||||||||||||||
Db          1 AAACACTAAGCTCTCTGGGC 20


RESULT 11
ADL34919
ID   ADL34919 standard; DNA; 20 BP.
XX
AC   ADL34919;
XX
DT   17-JUN-2004  (first entry)
XX
DE   Human PPAR-delta target site ID 50034.
XX
KW   antisense; PPAR-delta; human; hybridisation; inhibitor;
KW   phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW   hyperproliferative disorder; cancer; cytostatic; gene therapy; ds.
XX
OS   Homo sapiens.
XX
PN   US2004063129-A1.
XX
PD   01-APR-2004.
XX
PF   05-SEP-2003; 2003US-00655847.
XX
PR   31-MAY-2002; 2002US-00160807.
XX
PA   (GAAR/) GAARDE W.
PA   (FREI/) FREIER S M.
PA   (WATT/) WATT A T.
XX
PI   Gaarde W,  Freier SM,  Watt AT;
XX
DR   WPI; 2004-282460/26.
XX
PT   New antisense oligonucleotide, having a sequence targeted to a nucleic
PT   acid encoding PPAR-delta, useful for preparing a composition for treating
PT   hyperproliferative disorder, e.g., cancer.
XX
PS   Example 16; SEQ ID NO 217; 0pp; English.
XX
CC   This invention describes novel antisense oligonucleotides targeted to a
CC   nucleic acid encoding PPAR-delta, which specifically hybridise to and
CC   inhibit expression of PPAR-delta. The oligonucleotide specifically
CC   hybridises with at least an 8-nucleobase portion of an active site on the
CC   nucleic acid molecule encoding the PPAR-delta and comprises at least one
CC   modified internucleoside linkage, which is a phosphorothioate linkage, at
CC   least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar
CC   moiety or at least one modified nucleobase, which is a 5-methylcytosine.
```

```
CC   The antisense oligonucleotides are useful for preparing a composition for
CC   treating hyperproliferative disorders, e.g., cancer. The oligonucleotides
CC   of the invention have cytostatic activity and can be used for gene
CC   therapy.
XX
SQ   Sequence 20 BP; 8 A; 3 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match            40.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity  100.0%;  Pred. No. 4.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2056 TTCAGAGCAAAAGACTTGAG 2075
              ||||||||||||||||||||
Db          1 TTCAGAGCAAAAGACTTGAG 20


RESULT 12
ADL34775/c
ID   ADL34775 standard; DNA; 20 BP.
XX
AC   ADL34775;
XX
DT   17-JUN-2004  (first entry)
XX
DE   Antisense oligonucleotide ISIS 136916.
XX
KW   antisense; PPAR-delta; human; hybridisation; inhibitor;
KW   phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW   hyperproliferative disorder; cancer; cytostatic; gene therapy; ss;
KW   primer.
XX
OS   Synthetic.
XX
PN   US2004063129-A1.
XX
PD   01-APR-2004.
XX
PF   05-SEP-2003; 2003US-00655847.
XX
PR   31-MAY-2002; 2002US-00160807.
XX
PA   (GAAR/) GAARDE W.
PA   (FREI/) FREIER S M.
PA   (WATT/) WATT A T.
XX
PI   Gaarde W,  Freier SM,  Watt AT;
XX
DR   WPI; 2004-282460/26.
XX
PT   New antisense oligonucleotide, having a sequence targeted to a nucleic
PT   acid encoding PPAR-delta, useful for preparing a composition for treating
PT   hyperproliferative disorder, e.g., cancer.
XX
PS   Example 15; SEQ ID NO 73; 0pp; English.
XX
CC   This invention describes novel antisense oligonucleotides targeted to a
CC   nucleic acid encoding PPAR-delta, which specifically hybridise to and
CC   inhibit expression of PPAR-delta. The oligonucleotide specifically
CC   hybridises with at least an 8-nucleobase portion of an active site on the
CC   nucleic acid molecule encoding the PPAR-delta and comprises at least one
CC   modified internucleoside linkage, which is a phosphorothioate linkage, at
CC   least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar
CC   moiety or at least one modified nucleobase, which is a 5-methylcytosine.
CC   The antisense oligonucleotides are useful for preparing a composition for
CC   treating hyperproliferative disorders, e.g., cancer. The oligonucleotides
CC   of the invention have cytostatic activity and can be used for gene
CC   therapy.
XX
SQ   Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match            40.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity  100.0%;  Pred. No. 4.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAGCTCTCTGGGC 2105
              ||||||||||||||||||||
Db          20 AAACACTAAGCTCTCTGGGC 1


RESULT 13
ABZ10726/c
ID   ABZ10726 standard; DNA; 18 BP.
XX
AC   ABZ10726;
XX
DT   16-JAN-2003  (first entry)
XX
DE   Haematopoietic cell proliferation disorder related oligonucleotide #866.
XX
KW   Human; haematopoietic cell proliferation disorder; cytostatic;
KW   gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
KW   cytosine methylation state; probe; primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200277272-A2.
XX
PD   03-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-EP003401.
XX
PR   26-MAR-2001; 2001US-0278333P.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Berlin K,  Braun A,  Distler J,  Guetig D,  Howe A,  Mueller J;
PI   Olek A,  Piepenbrock C,  Adorjan P,  Grabs G,  Lesche R,  Leu E;
PI   Lewin A,  Lipscher E,  Maier S,  Model F,  Mueller V,  Otto T,  Pelet C;
PI   Schwope I,  Ziebarth H;
XX
DR   WPI; 2003-018942/01.
XX
PT   Detecting and differentiating between hematopoietic cell proliferative
PT   disorders, comprises contacting a target nucleic acid with a reagent that
PT   distinguishes between methylated and non-methylated CpG dinucleotides.
XX
PS   Claim 15; Page 59; 117pp; English.
XX
CC   The present invention describes a method for detecting and
CC   differentiating between haematopoietic cell proliferative disorders
CC   associated with at least 1 gene and/or their regulatory regions in a
CC   subject. The method comprises contacting a target nucleic acid in a
CC   biological sample obtained from the subject with at least 1 reagent,
CC   which distinguishes between methylated and non-methylated CpG
CC   dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
CC   represent specifically claimed nucleotide sequences from the present
CC   invention. Oligonucleotides from the present invention can be used: for
CC   differentiating between healthy haematopoietic cells and proliferative
CC   disorder haematopoietic cells; for differentiating between acute
CC   lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
CC   determining the cytosine methylation state and/or single nucleotide
CC   polymorphisms (SNPs) of haematopoietic cell proliferation disorder
CC   related sequences and their complements; and as primers for the
CC   amplification of haematopoietic cell proliferation disorder related DNA
CC   sequences. The nucleotide sequences from the present invention can also
CC   be used for detecting a predisposition to, differentiation between
CC   subclasses, diagnosis, prognosis, treatment and/or monitoring of
CC   haematopoietic cell proliferative disorders. The present method enables a
CC   highly specific classification of haematopoietic cell proliferative
CC   disorders allowing for improved and informed treatment of patients
XX
SQ   Sequence 18 BP; 3 A; 0 C; 5 G; 10 T; 0 U; 0 Other;

  Query Match            28.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity  93.8%;  Pred. No. 20;
```

```
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2079 TCCAAAGAAACACTAA 2094
                ||||||  |||||||||
Db         16 TCCAAACAAACACTAA 1


RESULT 14
ADB54738/c
ID   ADB54738 standard; DNA; 18 BP.
XX
AC   ADB54738;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Hybridisation oligonucleotide 276 used to analyse genomic DNA region.
XX
KW   colon cell proliferative disorder; non methylated CpG dinucleotide;
KW   cytostatic; cancer; adenoma; carcinoma; cytosine methylation state; ss;
KW   probe.
XX
OS   Unidentified.
XX
PN   WO2003072821-A2.
XX
PD   04-SEP-2003.
XX
PF   27-FEB-2003; 2003WO-EP002035.
XX
PR   27-FEB-2002; 2002EP-00004551.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Adorjan P,  Burger M,  Maier S,  Nimmrich I,  Becker E,  Lesche R;
PI   Rujan T,  Schmitt A;
XX
DR   WPI; 2003-731620/69.
XX
PT   Detecting and differentiating between colon cell proliferative disorders
PT   associated with a gene or its regulatory regions comprises contacting a
PT   target nucleic acid in a biological sample obtained from the subject with
PT   a reagent.
XX
PS   Claim 36; Page 42; 74pp; English.
XX
CC   The invention relates to a novel method for detecting and differentiating
CC   between colon cell proliferative disorders associated with at least one
CC   gene or its regulatory regions. The method comprises contacting a target
CC   nucleic acid in a biological sample obtained from the subject with at
CC   least one reagent or a series of reagents, where the reagent or series of
CC   reagents, distinguishes between methylated and non methylated CpG
CC   dinucleotides within the target nucleic acid. The molecules of the
CC   invention demonstrate cytostatic activity whilst the method may useful
CC   for detecting and differentiating between colon cell proliferative
CC   disorders, including cancers such as colon adenoma and colon carcinoma.
CC   The PNA (peptide nucleic acid)-oligomers are useful as probes for
CC   determining cytosine methylation state or single nucleotide
CC   polymorphisms. The current sequence is that of the hybridisation
CC   oligonucleotide of the invention which was used to analyse the genomic
CC   DNA region.
XX
SQ   Sequence 18 BP; 3 A; 0 C; 5 G; 10 T; 0 U; 0 Other;

  Query Match             28.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 20;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2079 TCCAAAGAAACACTAA 2094
                ||||||  |||||||||
Db         16 TCCAAACAAACACTAA 1


RESULT 15
ADC70291/c
ID   ADC70291 standard; DNA; 18 BP.
XX
AC   ADC70291;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Primer oligo used for analysing CpG islands in genomic DNA (SeqID 781).
XX
KW   PCR; primer; ss; lung cell proliferative disorder; CpG dinucleotide;
KW   adenocarcinoma; squamous cell carcinoma; cytostatic; probe; PNA-oligomer;
KW   cytosine methylation state.
XX
OS   Unidentified.
XX
PN   WO2003052135-A2.
XX
PD   26-JUN-2003.
XX
PF   10-DEC-2002; 2002WO-EP014026.
XX
PR   14-DEC-2001; 2001DE-01061625.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Burger M,  Field JK,  Genc B,  Liloglou T,  Lipscher E,  Maier S;
PI   Nimmrich I;
XX
DR   WPI; 2003-533029/50.
XX
PT   Detecting and differentiating cytosine methylation state of genomic DNA,
PT   useful for diagnosing, treating prognosticating and/or monitoring lung
PT   cell proliferative disorders e.g. adenocarcinoma and squamous cell
PT   carcinoma.
XX
PS   Claim 15; SEQ ID NO 781; 58pp; English.
XX
CC   This invention relates to a novel method for detecting and
CC   differentiating between lung cell proliferative disorders associated with
CC   at least one gene and/or their regulatory regions. Specifically, it
CC   refers to a method comprising contacting a target nucleic acid in a
CC   biological sample with at least one reagent, wherein the reagent is able
CC   to distinguish between methylated and non-methylated CpG dinucleotides
CC   present in the target DNA. As such, it is possible to further
CC   differentiate and diagnose medical conditions including adenocarcinoma
CC   and squamous cell carcinoma, and their respective adjacent lung tissue.
CC   The present invention describes cytostatic oligomers and PNA-oligomers
CC   that are useful as probes for determining the cytosine methylation state
CC   or single nucleotide polymorphisms (SNPs) of the target sequence. This
CC   oligonucleotide sequence is a primer oligomer used for the analysis of
CC   CpG positions within genomic DNA, used in an exemplification of the
CC   invention.
XX
SQ   Sequence 18 BP; 3 A; 0 C; 5 G; 10 T; 0 U; 0 Other;

  Query Match             28.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 20;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2079 TCCAAAGAAACACTAA 2094
                ||||||  |||||||||
Db         16 TCCAAACAAACACTAA 1


RESULT 16
ADE84512/c
ID   ADE84512 standard; DNA; 18 BP.
XX
AC   ADE84512;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human lymphoid cell proliferative disorder gene CpG analysis oligo #218.
```

```
XX
KW   lymphoid cell proliferative disorder; methylation;
KW   methylated CpG dinucleotide; single nucleotide polymorphism; SNP;
KW   diffuse large B-cell lymphoma; mantle cell lymphoma;
KW   chronic lymphocytic leukemia; small lymphocytic lymphoma;
KW   follicular lymphoma; diagnosis; prognosis; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003044226-A2.
XX
PD   30-MAY-2003.
XX
PF   25-NOV-2002; 2002WO-EP013265.
XX
PR   23-NOV-2001; 2001DE-01057491.
PR   28-DEC-2001; 2001DE-01064501.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Burger M,  Caldwell C,  Genc B,  Becker E,  Maier S,  Nimmrich I;
XX
DR   WPI; 2003-457621/43.
XX
PT   Detecting and differentiating between lymphoid cell proliferative
PT   disorders comprises contacting a target nucleic acid with at least one
PT   reagent that distinguishes between methylated and non-methylated CpG
PT   dinucleotides.
XX
PS   Claim 30; SEQ ID NO 508; 448pp; English.
XX
CC   The invention relates to a method of detecting and differentiating
CC   between lymphoid cell proliferative disorders associated with at least
CC   one gene and/or their regulatory regions in a subject by contacting a
CC   target nucleic acid in a biological sample obtained from the subject with
CC   at least one reagent or series of reagents that distinguish between
CC   methylated and non-methylated CpG dinucleotides within the target nucleic
CC   acid. The genes and/or their regulatory regions are preferably selected
CC   from MDR1, CSNK2B, EGR4, AR, CDK4, RB2, CDC25A, GPIb beta, MYOD1, CDH3,
CC   MYCL1, ELK1, ABL1, APC, BCL2, CDH1, CDKN1A, CDKN1B, CDKN2a, CDKN2B, FOS,
CC   GSTP1, HIC-1, MGMT, MLH1, MOS, MYC, PTEN, RBL2, TGFBR2, TP73, CDKNIC,
CC   GSK3beta, ESR1, APAF1, BAK1, BAX or HOXA5. Oligomers, peptide nucleic
CC   acid (PNA)-oligomers and/or isolated nucleic acids based on the sequences
CC   of the genes are useful for detecting the methylation state of all the
CC   CpG dinucleotides within one or more the sequences, or their complements,
CC   for determining the cytosine methylation state and or single nucleotide
CC   polymorphisms (SNPs), and for differentiating at least two of the medical
CC   conditions such as diffuse large B-cell lymphoma, mantle cell lymphoma,
CC   chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular
CC   lymphoma. They are also useful for detecting of a predisposition to,
CC   differentiation between subclasses, diagnosis, prognosis, treating and/or
CC   monitoring of lymphoid cell proliferative disorder. This sequence
CC   represents an oligonucleotide used to analyse of CpG positions within the
CC   above mentioned genes.
XX
SQ   Sequence 18 BP; 3 A; 0 C; 5 G; 10 T; 0 U; 0 Other;

  Query Match             28.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 20;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2079 TCCAAAGAAACACTAA 2094
              |||||| |||||||||
Db         16 TCCAAACAAACACTAA 1


RESULT 17
AAX75280
ID   AAX75280 standard; RNA; 17 BP.
XX
AC   AAX75280;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #808.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Mus sp.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 179; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 8 A; 3 C; 4 G; 0 T; 2 U; 0 Other;

  Query Match             27.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 22;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2072 TGAGCCATCCAAAGAAA 2088
              :||||||:| |||| ||
Db          1 UGAGCCAUCAAAAGGAA 17


RESULT 18
AAF47731/c
ID   AAF47731 standard; DNA; 15 BP.
XX
AC   AAF47731;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP3 oligonucleotide #1151.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
```

XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 7; Page 51; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 2 A; 1 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 24.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 27;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2076 CCATCCAAAGAAAC 2089
|||| |||||||||
Db 14 CCATTCAAAGAAAC 1

RESULT 19
AAF47730/c
ID AAF47730 standard; DNA; 15 BP.
XX
AC AAF47730;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP3 oligonucleotide #1150.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 7; Page 51; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 2 A; 1 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 24.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 27;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2076 CCATCCAAAGAAAC 2089
|||| |||||||||
Db 15 CCATTCAAAGAAAC 2

RESULT 20
AAT52513/c
ID AAT52513 standard; RNA; 15 BP.
XX
AC AAT52513;
XX
DT 25-MAR-2003 (revised)
DT 10-APR-1997 (first entry)
XX
DE Mouse ICAM hammerhead ribozyme target sequence (nt. position 2593).
XX
KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW intercellular adhesion molecule; rel A; tumour necrosis factor;
KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW translocation; chronic myelogenous leukaemia; CML; cancer;
KW Philadelphia chromosome; inflammation; autoimmune disease;
KW atherosclerosis; myocardial infarction; stroke; restenosis;
KW transplant rejection; rheumatoid arthritis; psoriasis;
KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW ss.
XX
OS Mus musculus.
XX
PN WO9523225-A2.

```
XX
PD   31-AUG-1995.
XX
PF   23-FEB-1995;   95WO-IB000156.
XX
PR   23-FEB-1994;   94US-00201109.
PR   29-MAR-1994;   94US-00218934.
PR   04-APR-1994;   94US-00222795.
PR   07-APR-1994;   94US-00224483.
PR   15-APR-1994;   94US-00227958.
PR   15-APR-1994;   94US-00228041.
PR   18-MAY-1994;   94US-00245736.
PR   06-JUL-1994;   94US-00271280.
PR   15-AUG-1994;   94US-00291932.
PR   16-AUG-1994;   94US-00291433.
PR   17-AUG-1994;   94US-00292620.
PR   19-AUG-1994;   94US-00293520.
PR   02-SEP-1994;   94US-00300000.
PR   08-SEP-1994;   94US-00303039.
PR   23-SEP-1994;   94US-00311486.
PR   23-SEP-1994;   94US-00311749.
PR   28-SEP-1994;   94US-00314397.
PR   03-OCT-1994;   94US-00316771.
PR   07-OCT-1994;   94US-00319492.
PR   11-OCT-1994;   94US-00321993.
PR   04-NOV-1994;   94US-00334847.
PR   10-NOV-1994;   94US-00337608.
PR   28-NOV-1994;   94US-00345516.
PR   16-DEC-1994;   94US-00357577.
PR   23-DEC-1994;   94US-00363233.
PR   30-JAN-1995;   95US-00380734.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Chowrira B,  Direnzo A,  Draper KG,  Dudycz LW;
PI   Grimm S,  Karpeisky A,  Kisich K,  Matulic-Adamic J,  Mcswiggen JA;
PI   Modak A,  Pavco P,  Beigleman L,  Sullivan SM,  Sweedler D,  Thompson JD;
PI   Tracz D,  Usman N,  Wincott FE,  Woolf T;
XX
DR   WPI; 1995-351090/45.
XX
PT   Ribozymes having modified bases and methods for producing them - for use
PT   in inhibiting disease related genes.
XX
PS   Claim 2; Page 180; 407pp; English.
XX
CC   The present sequence represents a preferred target sequence for an
CC   enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
CC   nucleotide base position indicated in the DE line. Regions of the mRNA
CC   that do not form secondary folding structures and that contain potential
CC   hammerhead and hairpin ribozyme cleavage sites were identified by
CC   computer analysis. Ribozymes directed against these mRNA sequences were
CC   designed and synthesised with modifications that improve their nuclease
CC   resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC   inhibit ICAM-1 expression, making them useful for reducing transplant
CC   rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC   asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC   correct PI field.)
XX
SQ   Sequence 15 BP; 0 A; 5 C; 2 G; 0 T; 8 U; 0 Other;

  Query Match             24.0%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 31;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2058 CAGAGCAAAAGA 2069
              ||||||||||||
Db         14 CAGAGCAAAAGA 3


RESULT 21
ABF44787
ID   ABF44787 standard; DNA; 13 BP.
XX
AC   ABF44787;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 144784 for detecting SNP TSC0036421.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 144784; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             22.8%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 30;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2077 CATCCAAAGAAAC 2089
              |||||||| ||||
Db          1 CATCCAAACAAAC 13


RESULT 22
ABC05028/c
ID   ABC05028 standard; DNA; 13 BP.
XX
AC   ABC05028;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 5019 for detecting SNP TSC0001741.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
```

PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 5019; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 22.8%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 30;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2082 AAAGAAACACTAA 2094
||| |||||||||
Db 13 AAACAAACACTAA 1

RESULT 23
ABC05029
ID ABC05029 standard; DNA; 13 BP.
XX
AC ABC05029;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 5020 for detecting SNP TSC0001741.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 5020; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 22.8%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 30;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2082 AAAGAAACACTAA 2094
||| |||||||||
Db 1 AAACAAACACTAA 13

RESULT 24
ABF48836/c
ID ABF48836 standard; DNA; 13 BP.
XX
AC ABF48836;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 148833 for detecting SNP TSC0037567.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 148833; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

```
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 1 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             22.8%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 30;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2089 CACTAAGCTCTCT 2101
                ||||| |||||||
Db         13 CACTACGCTCTCT 1


RESULT 25
ABF44786/c
ID   ABF44786 standard; DNA; 13 BP.
XX
AC   ABF44786;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 144783 for detecting SNP TSC0036421.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 144783; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             22.8%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 30;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2077 CATCCAAAGAAAC 2089
                ||||||| ||||
Db         13 CATCCAAACAAAC 1


RESULT 26
ABF48837
ID   ABF48837 standard; DNA; 13 BP.
XX
AC   ABF48837;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 148834 for detecting SNP TSC0037567.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 148834; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 6 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             22.8%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 30;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2089 CACTAAGCTCTCT 2101
                ||||| |||||||
Db          1 CACTACGCTCTCT 13


RESULT 27
ABF26976/c
ID   ABF26976 standard; DNA; 13 BP.
XX
AC   ABF26976;
XX
DT   21-FEB-2002  (first entry)
XX
```

```
DE   Oligonucleotide SEQ ID NO 126973 for detecting SNP TSC0031781.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 126973; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 1 Other;

  Query Match             22.0%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 33;
  Matches   11;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2085 GAAACACTAAGCT 2097
              :|||||||||  ||
Db         13 RAAACACTAAACT 1


RESULT 28
ABF26977
ID   ABF26977 standard; DNA; 13 BP.
XX
AC   ABF26977;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 126974 for detecting SNP TSC0031781.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 126974; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 1 Other;

  Query Match             22.0%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 33;
  Matches   11;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2085 GAAACACTAAGCT 2097
              :|||||||||  ||
Db         13 RAAACACTAAACT 1


RESULT 29
ABF85994/c
ID   ABF85994 standard; DNA; 13 BP.
XX
AC   ABF85994;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 185991 for detecting SNP TSC0045833.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
```

```
PS   Claim 1; SEQ ID NO 185991; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 1 Other;

  Query Match             22.0%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 33;
  Matches   11;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2082 AAAGAAACACTAA 2094
              :|| |||||||||
Db         13 RAACAAACACTAA 1


RESULT 30
ABF87456/c
ID   ABF87456 standard; DNA; 13 BP.
XX
AC   ABF87456;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 187453 for detecting SNP TSC0046211.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 187453; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 5 G; 4 T; 0 U; 1 Other;

  Query Match             22.0%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 33;
  Matches   11;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2088 ACACTAAGCTCTC 2100
              :|||||| |||||
Db         13 RCACTAAACTCTC 1


RESULT 31
ABF85995
ID   ABF85995 standard; DNA; 13 BP.
XX
AC   ABF85995;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 185992 for detecting SNP TSC0045833.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 185992; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 1 Other;

  Query Match             22.0%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 33;
  Matches   11;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2082 AAAGAAACACTAA 2094
              :|| |||||||||
Db          1 RAACAAACACTAA 13
```

```
RESULT 32
ABF87457
ID   ABF87457 standard; DNA; 13 BP.
XX
AC   ABF87457;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 187454 for detecting SNP TSC0046211.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 187454; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 1 Other;

  Query Match             22.0%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 33;
  Matches   11;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2088 ACACTAAGCTCTC 2100
              :|||||| |||||
Db          1 RCACTAAACTCTC 13


RESULT 33
ABI58987
ID   ABI58987 standard; DNA; 12 BP.
XX
AC   ABI58987;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 358960 for detecting SNP TSC0009167.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 358960; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 35;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2083 AAGAAACACTAA 2094
              || |||||||||
Db          1 AAAAAACACTAA 12


RESULT 34
ABH75972/c
ID   ABH75972 standard; DNA; 12 BP.
XX
AC   ABH75972;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 275965 for detecting SNP TSC0004052.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
```

PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 275965; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 35;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2079 TCCAAAGAAACA 2090
||||||| |||||
Db 12 TCCAAAAAAACA 1

RESULT 35
ABI44086
ID ABI44086 standard; DNA; 12 BP.
XX
AC ABI44086;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 344059 for detecting SNP TSC0043357.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 344059; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 1 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 35;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2065 AAAGACTTGAGC 2076
||||| ||||||
Db 1 AAAGATTTGAGC 12

RESULT 36
ABI74566/c
ID ABI74566 standard; DNA; 12 BP.
XX
AC ABI74566;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 374539 for detecting SNP TSC0060768.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 374539; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 3 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 12;

```
  Best Local Similarity   91.7%;  Pred. No. 35;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2065 AAAGACTTGAGC 2076
              ||||| ||||||
Db         12 AAAGATTTGAGC 1


RESULT 37
ABI73012
ID   ABI73012 standard; DNA; 12 BP.
XX
AC   ABI73012;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 372985 for detecting SNP TSC0059764.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 372985; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 35;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2078 ATCCAAAGAAAC 2089
              ||||||| ||||
Db          1 ATCCAAATAAAC 12


RESULT 38
ABI40361
ID   ABI40361 standard; DNA; 12 BP.
XX
AC   ABI40361;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 340334 for detecting SNP TSC0041469.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 340334; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 35;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2081 CAAAGAAACACT 2092
              |||| |||||||
Db          1 CAAACAAACACT 12


RESULT 39
ABI54654
ID   ABI54654 standard; DNA; 12 BP.
XX
AC   ABI54654;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 354627 for detecting SNP TSC0049190.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
```

PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 354627; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 35;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2087 AACACTAAGCTC 2098
||||||||| |||
Db 1 AACACTAAACTC 12

RESULT 40
ABI61429
ID ABI61429 standard; DNA; 12 BP.
XX
AC ABI61429;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 361402 for detecting SNP TSC0052625.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 361402; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 35;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2081 CAAAGAAACACT 2092
|||| |||||||
Db 1 CAAAAAAACACT 12

RESULT 41
ABI28939/c
ID ABI28939 standard; DNA; 12 BP.
XX
AC ABI28939;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 328912 for detecting SNP TSC0034651.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 328912; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

```
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 0 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 35;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2080 CCAAAGAAACAC 2091
              ||||| ||||||
Db         12 CCAAAAAAACAC 1


RESULT 42
ABI68635/c
ID   ABI68635 standard; DNA; 12 BP.
XX
AC   ABI68635;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 368608 for detecting SNP TSC0057113.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 368608; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 35;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAGCT 2097
              ||||||||| ||
Db         12 AAACACTAATCT 1


RESULT 43
ABH86185
ID   ABH86185 standard; DNA; 12 BP.
XX
AC   ABH86185;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 286178 for detecting SNP TSC0012609.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 286178; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 35;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAGCT 2097
              ||||||||| ||
Db          1 AAACACTAATCT 12


RESULT 44
ABI77309/c
ID   ABI77309 standard; DNA; 12 BP.
XX
AC   ABI77309;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 377282 for detecting SNP TSC0062244.
XX
```

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 377282; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 35;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2076 CCATCCAAAGAA 2087
||||||||| ||
Db 12 CCATCCAAACAA 1

RESULT 45
ABH88737/c
ID ABH88737 standard; DNA; 12 BP.
XX
AC ABH88737;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 288730 for detecting SNP TSC0013649.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 288730; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 35;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2083 AAGAAACACTAA 2094
|| |||||||||
Db 12 AAAAAACACTAA 1

RESULT 46
ABI78875/c
ID ABI78875 standard; DNA; 12 BP.
XX
AC ABI78875;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 378848 for detecting SNP TSC0062959.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 378848; 29pp + Sequence Listing; German.
XX

```
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 35;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2081 CAAAGAAACACT 2092
                ||||  |||||||
Db         12 CAAATAAACACT 1


RESULT 47
ABH69603
ID   ABH69603 standard; DNA; 12 BP.
XX
AC   ABH69603;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 269580 for detecting SNP TSC0001812.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 269580; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 35;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2083 AAGAAACACTAA 2094
                ||  |||||||||
Db          1 AATAAACACTAA 12


RESULT 48
ABH82641/c
ID   ABH82641 standard; DNA; 12 BP.
XX
AC   ABH82641;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 282634 for detecting SNP TSC0010918.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 282634; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 35;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2081 CAAAGAAACACT 2092
                ||||  |||||||
Db         12 CAAACAAACACT 1


RESULT 49
ABI57188
```

ID ABI57188 standard; DNA; 12 BP.
XX
AC ABI57188;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 357161 for detecting SNP TSC0050498.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 357161; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 35;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2080 CCAAAGAAACAC 2091
||||| ||||||
Db 1 CCAAAAAAACAC 12

RESULT 50
ABI27995/c
ID ABI27995 standard; DNA; 12 BP.
XX
AC ABI27995;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 327968 for detecting SNP TSC0034004.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 327968; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 35;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2082 AAAGAAACACTA 2093
||| ||||||||
Db 12 AAACAAACACTA 1

RESULT 51
ABI44646/c
ID ABI44646 standard; DNA; 12 BP.
XX
AC ABI44646;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 344619 for detecting SNP TSC0006871.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX

```
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 344619; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 35;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2077 CATCCAAAGAAA 2088
                ||||||||  |||
Db         12 CATCCAAAAAAA 1


RESULT 52
ABI20258/c
ID   ABI20258 standard; DNA; 12 BP.
XX
AC   ABI20258;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 320231 for detecting SNP TSC0029616.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 320231; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 35;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2087 AACACTAAGCTC 2098
                ||||||||  |||
Db         12 AACACTAACCTC 1


RESULT 53
ABH89528
ID   ABH89528 standard; DNA; 12 BP.
XX
AC   ABH89528;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 289521 for detecting SNP TSC0013970.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 289521; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 35;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       2076 CCATCCAAAGAA 2087
              |||||||||  ||
Db          1 CCATCCAAAAAA 12
```

RESULT 54
ABI58394/c
ID ABI58394 standard; DNA; 12 BP.
XX
AC ABI58394;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 358367 for detecting SNP TSC0051084.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 358367; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 35;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2078 ATCCAAAGAAAC 2089
              ||||||| ||||
Db         12 ATCCAAAAAAAC 1
```

RESULT 55
ABI65055
ID ABI65055 standard; DNA; 12 BP.
XX
AC ABI65055;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 365028 for detecting SNP TSC0054877.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 365028; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 35;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2083 AAGAAACACTAA 2094
              || |||||||||
Db          1 AACAAACACTAA 12
```

RESULT 56
AAV06890
ID AAV06890 standard; DNA; 13 BP.
XX
AC AAV06890;
XX
DT 01-JUL-1998 (first entry)
XX
DE One from an array of 58 cystic fibrosis oligonucleotides.
XX
KW H-ras; wild-type; immobilising; diagnosis; ethylene acrylic acid;
KW ethylene methacrylic acid; polypropylene; biotin; cystic fibrosis; array;
KW ss.
XX
OS Synthetic.
XX
PN WO9746597-A1.
XX
PD 11-DEC-1997.
XX

```
PF   22-MAY-1997;   97WO-US008880.
XX
PR   05-JUN-1996;   96US-00658664.
XX
PA   (BECI ) BECKMAN INSTR INC.
XX
PI   Milton RC;
XX
DR   WPI; 1998-051910/05.
XX
PT   Polymeric reagents for immobilising biopolymers - are stable under
PT   synthesis conditions.
XX
PS   Example 7; Fig 19; 66pp; English.
XX
CC   The present sequence represents one of an array of 58 cystic fibrosis
CC   oligonucleotides. The invention relates to a new reagent for immobilising
CC   a biopolymer. It comprises a solid support fabricated from a polymeric
CC   material having at least one surface comprising pendant acyl fluoride
CC   functionalities. The reagent is stable under conditions for synthesising
CC   and immobilising biopolymers and is stable under conditions used to
CC   analyse the biopolymers. The reagents can be formed into devices which
CC   are physically rugged and inexpensive which can be used in analytical and
CC   diagnostic procedures
XX
SQ   Sequence 13 BP; 5 A; 5 C; 1 G; 2 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2072 TGAGCCATCCAA 2083
                ||| ||||||||
Db          2 TGAACCATCCAA 13


RESULT 57
ABC52017
ID   ABC52017 standard; DNA; 13 BP.
XX
AC   ABC52017;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 52034 for detecting SNP TSC0014491.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 52034; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2079 TCCAAAGAAACA 2090
                ||||||  |||||
Db          1 TCCAAATAAACA 12


RESULT 58
ABC52018/c
ID   ABC52018 standard; DNA; 13 BP.
XX
AC   ABC52018;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 52035 for detecting SNP TSC0014491.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 52035; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
```

```
  Query Match           20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2079 TCCAAAGAAACA 2090
              |||||| |||||
Db         13 TCCAAACAAACA 2


RESULT 59
ABC15655
ID   ABC15655 standard; DNA; 13 BP.
XX
AC   ABC15655;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 15662 for detecting SNP TSC0003464.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 15662; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 10 A; 2 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match           20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2083 AAGAAACACTAA 2094
              || |||||||||
Db          1 AAAAAACACTAA 12


RESULT 60
ABH12189
ID   ABH12189 standard; DNA; 13 BP.
XX
AC   ABH12189;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 212166 for detecting SNP TSC0001691.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 212166; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match           20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2083 AAGAAACACTAA 2094
              || |||||||||
Db          1 AACAAACACTAA 12


RESULT 61
ABC34878/c
ID   ABC34878 standard; DNA; 13 BP.
XX
AC   ABC34878;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 34895 for detecting SNP TSC0011082.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
```

PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 34895; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 39;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2083 AAGAAACACTAA 2094
|| |||||||||
Db 13 AAAAAACACTAA 2

RESULT 62
ABF16561
ID ABF16561 standard; DNA; 13 BP.
XX
AC ABF16561;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 116558 for detecting SNP TSC0029174.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 116558; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 39;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2076 CCATCCAAAGAA 2087
|||||||| ||
Db 2 CCATCCAAAAAA 13

RESULT 63
ABF75305
ID ABF75305 standard; DNA; 13 BP.
XX
AC ABF75305;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 175302 for detecting SNP TSC0043563.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 175302; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

```
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 9 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2077 CATCCAAAGAAA 2088
                ||||||||  |||
Db          2 CATCCAAAAAAA 13


RESULT 64
ABF30114/c
ID   ABF30114 standard; DNA; 13 BP.
XX
AC   ABF30114;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 130111 for detecting SNP TSC0032525.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173:
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 130111; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 1 A; 0 C; 3 G; 9 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2083 AAGAAACACTAA 2094
                ||  |||||||||
Db          13 AACAAACACTAA 2


RESULT 65
ABF30115
ID   ABF30115 standard; DNA; 13 BP.
XX
AC   ABF30115;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 130112 for detecting SNP TSC0032525.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 130112; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 9 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2083 AAGAAACACTAA 2094
                ||  |||||||||
Db          1 AACAAACACTAA 12


RESULT 66
ABF44362/c
ID   ABF44362 standard; DNA; 13 BP.
XX
AC   ABF44362;
XX
DT   21-FEB-2002  (first entry)
XX
```

DE Oligonucleotide SEQ ID NO 144359 for detecting SNP TSC0036296.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 144359; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 39;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2076 CCATCCAAAGAA 2087
||||||||| ||
Db 12 CCATCCAAAAAA 1

RESULT 67
ABF61404/c
ID ABF61404 standard; DNA; 13 BP.
XX
AC ABF61404;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 161401 for detecting SNP TSC0040638.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 161401; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 39;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2083 AAGAAACACTAA 2094
|| |||||||||
Db 13 AATAAACACTAA 2

RESULT 68
ABC52019
ID ABC52019 standard; DNA; 13 BP.
XX
AC ABC52019;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 52036 for detecting SNP TSC0014491.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

```
PS   Claim 1; SEQ ID NO 52036; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2079 TCCAAAGAAACA 2090
                ||||||  |||||
Db          1 TCCAAACAAACA 12


RESULT 69
ABC34879
ID   ABC34879 standard; DNA; 13 BP.
XX
AC   ABC34879;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 34896 for detecting SNP TSC0011082.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 34896; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 9 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2083 AAGAAACACTAA 2094
                ||  |||||||||
Db          1 AAAAAACACTAA 12


RESULT 70
ABC61946/c
ID   ABC61946 standard; DNA; 13 BP.
XX
AC   ABC61946;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 61963 for detecting SNP TSC0016466.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 61963; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2087 AACACTAAGCTC 2098
                ||||||| |||
Db         13 AACACTAAACTC 2
```

```
RESULT 71
ABF26456/c
ID   ABF26456 standard; DNA; 13 BP.
XX
AC   ABF26456;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 126453 for detecting SNP TSC0031640.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 126453; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match            20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity  91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAGCT 2097
             ||||||||| ||
Db         12 AAACACTAAACT 1


RESULT 72
ABF44363
ID   ABF44363 standard; DNA; 13 BP.
XX
AC   ABF44363;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 144360 for detecting SNP TSC0036296.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 144360; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match            20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity  91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2076 CCATCCAAAGAA 2087
             ||||||||| ||
Db          2 CCATCCAAAAAA 13


RESULT 73
ABH56791
ID   ABH56791 standard; DNA; 13 BP.
XX
AC   ABH56791;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 256768 for detecting SNP TSC0062521.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
```

PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 256768; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 39;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2083 AAGAAACACTAA 2094
|| |||||||||
Db 1 AATAAACACTAA 12

RESULT 74
ABC52016/c
ID ABC52016 standard; DNA; 13 BP.
XX
AC ABC52016;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 52033 for detecting SNP TSC0014491.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 52033; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 39;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2079 TCCAAAGAAACA 2090
|||||| |||||
Db 13 TCCAAATAAACA 2

RESULT 75
ABH42205
ID ABH42205 standard; DNA; 13 BP.
XX
AC ABH42205;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 242182 for detecting SNP TSC0004948.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 242182; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 13;

```
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2082 AAAGAAACACTA 2093
              ||| ||||||||
Db          1 AAACAAACACTA 12


RESULT 76
ABC15654/c
ID   ABC15654 standard; DNA; 13 BP.
XX
AC   ABC15654;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 15661 for detecting SNP TSC0003464.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 15661; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 1 A; 0 C; 2 G; 10 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2083 AAGAAACACTAA 2094
              || |||||||||
Db         13 AAAAAACACTAA 2


RESULT 77
ABH41536/c
ID   ABH41536 standard; DNA; 13 BP.
XX
AC   ABH41536;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 241513 for detecting SNP TSC0058902.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 241513; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAGCT 2097
              ||||||||| ||
Db         13 AAACACTAAACT 2


RESULT 78
ABH56790/c
ID   ABH56790 standard; DNA; 13 BP.
XX
AC   ABH56790;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 256767 for detecting SNP TSC0062521.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
```

PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 256767; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 39;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2083 AAGAAACACTAA 2094
|| |||||||||
Db 13 AATAAACACTAA 2

RESULT 79
ABF26457
ID ABF26457 standard; DNA; 13 BP.
XX
AC ABF26457;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 126454 for detecting SNP TSC0031640.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 126454; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 39;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2086 AAACACTAAGCT 2097
|||||||| ||
Db 2 AAACACTAAACT 13

RESULT 80
ABC95309
ID ABC95309 standard; DNA; 13 BP.
XX
AC ABC95309;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 95326 for detecting SNP TSC0023732.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 95326; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

```
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2083 AAGAAACACTAA 2094
              || |||||||||
Db          1 AATAAACACTAA 12


RESULT 81
ABF25417
ID   ABF25417 standard; DNA; 13 BP.
XX
AC   ABF25417;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 125414 for detecting SNP TSC0031349.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 125414; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2082 AAAGAAACACTA 2093
              ||| ||||||||
Db          2 AAAAAAACACTA 13


RESULT 82
ABC90389
ID   ABC90389 standard; DNA; 13 BP.
XX
AC   ABC90389;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 90406 for detecting SNP TSC0022655.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 90406; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2088 ACACTAAGCTCT 2099
              ||||||| ||||
Db          2 ACACTAAACTCT 13


RESULT 83
ABC95308/c
ID   ABC95308 standard; DNA; 13 BP.
XX
AC   ABC95308;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 95325 for detecting SNP TSC0023732.
XX
```

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 95325; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 39;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2083 AAGAAACACTAA 2094
|| |||||||||
Db 13 AATAAACACTAA 2

RESULT 84
ABC05733
ID ABC05733 standard; DNA; 13 BP.
XX
AC ABC05733;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 5724 for detecting SNP TSC0001868.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 5724; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 39;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2083 AAGAAACACTAA 2094
|| |||||||||
Db 2 AAAAAACACTAA 13

RESULT 85
ABF75304/c
ID ABF75304 standard; DNA; 13 BP.
XX
AC ABF75304;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 175301 for detecting SNP TSC0043563.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 175301; 29pp + Sequence Listing; German.
XX

```
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 1 A; 0 C; 3 G; 9 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2077 CATCCAAAGAAA 2088
              |||||||| |||
Db         12 CATCCAAAAAAA 1


RESULT 86
ABH42204/c
ID   ABH42204 standard; DNA; 13 BP.
XX
AC   ABH42204;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 242181 for detecting SNP TSC0004948.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 242181; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2082 AAAGAAACACTA 2093
              ||| ||||||||
Db         13 AAACAAACACTA 2


RESULT 87
ABF03883
ID   ABF03883 standard; DNA; 13 BP.
XX
AC   ABF03883;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 103880 for detecting SNP TSC0025984.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 103880; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2083 AAGAAACACTAA 2094
              || |||||||||
Db          1 AAAAAACACTAA 12


RESULT 88
ABC05732/c
```

```
ID   ABC05732 standard; DNA; 13 BP.
XX
AC   ABC05732;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 5723 for detecting SNP TSC0001868.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 5723; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match            20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity  91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2083 AAGAAACACTAA 2094
              || |||||||||
Db         12 AAAAAACACTAA 1


RESULT 89
ABC61947
ID   ABC61947 standard; DNA; 13 BP.
XX
AC   ABC61947;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 61964 for detecting SNP TSC0016466.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 61964; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match            20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity  91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2087 AACACTAAGCTC 2098
              |||||||| |||
Db          1 AACACTAAACTC 12


RESULT 90
ABH12188/c
ID   ABH12188 standard; DNA; 13 BP.
XX
AC   ABH12188;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 212165 for detecting SNP TSC0001691.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
```

DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 212165; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 39;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2083 AAGAAACACTAA 2094
|| |||||||||
Db 13 AACAAACACTAA 2

RESULT 91
ABF03882/c
ID ABF03882 standard; DNA; 13 BP.
XX
AC ABF03882;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 103879 for detecting SNP TSC0025984.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 103879; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 39;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2083 AAGAAACACTAA 2094
|| |||||||||
Db 13 AAAAAACACTAA 2

RESULT 92
ABF61405
ID ABF61405 standard; DNA; 13 BP.
XX
AC ABF61405;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 161402 for detecting SNP TSC0040638.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 161402; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 20.8%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 39;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2083 AAGAAACACTAA 2094
              || |||||||||
Db          1 AATAAACACTAA 12
```

RESULT 93
ABC90388/c
ID ABC90388 standard; DNA; 13 BP.
XX
AC ABC90388;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 90405 for detecting SNP TSC0022655.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 90405; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;

```
  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2088 ACACTAAGCTCT 2099
              ||||||| ||||
Db         12 ACACTAAACTCT 1
```

RESULT 94
ABF16560/c
ID ABF16560 standard; DNA; 13 BP.
XX
AC ABF16560;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 116557 for detecting SNP TSC0029174.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 116557; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

```
  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2076 CCATCCAAAGAA 2087
              ||||||||| ||
Db         12 CCATCCAAAAAA 1
```

RESULT 95
ABF25416/c
ID ABF25416 standard; DNA; 13 BP.
XX
AC ABF25416;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 125413 for detecting SNP TSC0031349.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX

```
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 125413; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2082 AAAGAAACACTA 2093
                ||| ||||||||
Db         12 AAAAAAACACTA 1


RESULT 96
ABH41537
ID   ABH41537 standard; DNA; 13 BP.
XX
AC   ABH41537;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 241514 for detecting SNP TSC0058902.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 241514; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 39;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAGCT 2097
                ||||||||| ||
Db          1 AAACACTAAACT 12


RESULT 97
AAQ96819/c
ID   AAQ96819 standard; DNA; 10 BP.
XX
AC   AAQ96819;
XX
DT   16-OCT-2003  (revised)
DT   26-MAR-1996  (first entry)
XX
DE   HIV-1 NL4-3 nef gene nucleotide deletion 414.
XX
KW   HIV-1; AIDS; attenuation; vaccine; nef gene; avirulence; ss.
XX
OS   Human immunodeficiency virus 1.
XX
PN   WO9521912-A1.
XX
PD   17-AUG-1995.
XX
PF   14-FEB-1995;   95WO-AU000063.
XX
PR   14-FEB-1994;   94AU-00003864.
PR   21-FEB-1994;   94AU-00004002.
PR   23-DEC-1994;   94AU-00000284.
XX
PA   (MACF-) MACFARLANE BURNET CENT MEDICAL.
PA   (AURE-) AUSTRALIAN RED CROSS SOC.
XX
PI   Deacon NJ,  Learmont JC,  Mcphee DA,  Crowe S,  Cooper D;
XX
DR   WPI; 1995-293115/38.
XX
PT   New non-pathogenic HIV-1 strain carrying a deletion in its nef gene or
PT   LTR region - can be used in a vaccine to inhibit/reduce productive
PT   infection in an individual by a pathogenic strain.
XX
PS   Claim 13; Page 193; 301pp; English.
XX
CC   Attenuation of pathogenic HIV-1 strain NL4-3 involves deletion of 1 or
CC   more decanucleotides (AAQ96406-Q97018) from the nef gene and/or 1 or more
CC   decanucleotides (AAQ97019-Q97166) from the LTR region; the sequence of
CC   AAQ96406 corresponds to nucleotides 1-10 of the nef gene (AAQ96141). The
CC   resulting avirulent HIV strains are still capable of inducing an immune
CC   response in humans, and enable the generation of therapeutic, diagnostic
CC   and targeting agents against HIV-1 infection. (Updated on 16-OCT-2003 to
CC   standardise OS field)
```

```
XX
SQ   Sequence 10 BP; 1 A; 1 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             20.0%;  Score 10;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 30;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2076 CCATCCAAAG 2085
              ||||||||||
Db         10 CCATCCAAAG 1


RESULT 98
AAQ97069
ID   AAQ97069 standard; DNA; 10 BP.
XX
AC   AAQ97069;
XX
DT   16-OCT-2003  (revised)
DT   27-MAR-1996  (first entry)
XX
DE   HIV-1 NL4-3 LTR nucleotide deletion 51.
XX
KW   HIV-1; AIDS; attenuation; vaccine; nef gene; avirulence; ss.
XX
OS   Human immunodeficiency virus 1.
XX
PN   WO9521912-A1.
XX
PD   17-AUG-1995.
XX
PF   14-FEB-1995;   95WO-AU000063.
XX
PR   14-FEB-1994;   94AU-00003864.
PR   21-FEB-1994;   94AU-00004002.
PR   23-DEC-1994;   94AU-00000284.
XX
PA   (MACF-) MACFARLANE BURNET CENT MEDICAL.
PA   (AURE-) AUSTRALIAN RED CROSS SOC.
XX
PI   Deacon NJ,  Learmont JC,  Mcphee DA,  Crowe S,  Cooper D;
XX
DR   WPI; 1995-293115/38.
XX
PT   New non-pathogenic HIV-1 strain carrying a deletion in its nef gene or
PT   LTR region - can be used in a vaccine to inhibit/reduce productive
PT   infection in an individual by a pathogenic strain.
XX
PS   Claim 14; Page 197; 301pp; English.
XX
CC   Attenuation of pathogenic HIV-1 strain NL4-3 involves deletion of 1 or
CC   more decanucleotides (AAQ96406-Q97018) from the nef gene and/or 1 or more
CC   decanucleotides (AAQ97019-Q97166) from the LTR region; the sequence of
CC   AAQ96406 corresponds to nucleotides 1-10 of the nef gene (AAQ96141). The
CC   resulting avirulent HIV strains are still capable of inducing an immune
CC   response in humans, and enable the generation of therapeutic, diagnostic
CC   and targeting agents against HIV-1 infection. (Updated on 16-OCT-2003 to
CC   standardise OS field)
XX
SQ   Sequence 10 BP; 1 A; 3 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             20.0%;  Score 10;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 30;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2094 AGCTCTCTGG 2103
              ||||||||||
Db          1 AGCTCTCTGG 10


RESULT 99
AAZ82752
ID   AAZ82752 standard; DNA; 10 BP.
XX
AC   AAZ82752;
XX
DT   07-APR-2000  (first entry)
XX
DE   Metastatic breast tumour cell upregulated transcript tag #1986.
XX
KW   Human; metastatic breast tumour tissue; breast cancer; tag; primer;
KW   non-metastatic breast tumour tissue; gene therapy; anticancer;
KW   antimetastatic; vaccine; diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9965928-A2.
XX
PD   23-DEC-1999.
XX
PF   18-JUN-1999;   99WO-US013647.
XX
PR   19-JUN-1998;   98US-0089853P.
PR   19-JUN-1998;   98US-0089997P.
PR   19-JUN-1998;   98US-0090039P.
PR   19-JUN-1998;   98US-0090040P.
PR   19-JUN-1998;   98US-0090041P.
XX
PA   (GENZ ) GENZYME CORP.
PA   (ROBE/) ROBERTS B L.
PA   (SHAN/) SHANKARA S.
XX
PI   Roberts BL,  Shankara S;
XX
DR   WPI; 2000-106079/09.
XX
PT   Isolated polynucleotides differentially expressed between metastatic and
PT   non-metastatic breast cancer cells, useful for diagnosis, prevention and
PT   treatment of cancer.
XX
PS   Claim 1; Page 112; 219pp; English.
XX
CC   AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
CC   that are preferentially transcribed in the metastatic breast tumour
CC   tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
CC   to AAZ86677 represent tags corresponding to distinct transcripts that are
CC   preferentially transcribed in the primary or non-metastatic breast tumour
CC   tissue (i.e. are downregulated in metastatic breast tumour cells). These
CC   transcripts can be used for diagnosis, prognosis, monitoring and
CC   treatment of breast cancer, particularly where metastatic. Diagnosis is
CC   by standard immunoassays or hybridisation/amplification reactions.
CC   Compounds that modulate expression of the transcripts are potentially
CC   useful for treatment of (metastatic) breast cancer, while promoters from
CC   the transcripts are used to direct expression, in selected cell types, of
CC   e.g. therapeutic genes (also ribozymes or antisense sequences),
CC   particularly an antigen-encoding sequence for use in gene or cell-based
CC   vaccines. Polypeptides encoded by the transcripts are also useful in
CC   vaccines; for diagnosing breast cancer and for raising specific
CC   antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
CC   agents. Host cells that produce the polypeptides can be used to expand
CC   and isolate populations of educated, antigen-specific immune effecter
CC   cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
CC   immunotherapy
XX
SQ   Sequence 10 BP; 2 A; 3 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             20.0%;  Score 10;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 30;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2092 TAAGCTCTCT 2101
              ||||||||||
Db          1 TAAGCTCTCT 10


RESULT 100
```

```
ABV63489/c
ID   ABV63489 standard; cDNA; 11 BP.
XX
AC   ABV63489;
XX
DT   21-OCT-2002  (first entry)
XX
DE   Human skin EST 1275.
XX
KW   Human; skin; dermatological; vulnerary; antipsoriatic; antiseborrhaeic;
KW   immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW   psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS   Homo sapiens.
XX
PN   WO200253774-A2.
XX
PD   11-JUL-2002.
XX
PF   20-DEC-2001; 2001WO-EP015179.
XX
PR   03-JAN-2001; 2001DE-01000127.
XX
PA   (HENK ) HENKEL KGAA.
XX
PI   Petersohn D,  Conradt M,  Hofmann K;
XX
DR   WPI; 2002-590638/63.
XX
PT   In vitro identification of skin-expressed genes, useful for determining
PT   homeostasis and identifying cosmetic or pharmaceutical agents against
PT   e.g. skin cancer.
XX
PS   Disclosure; Page 60; 1345pp; German.
XX
CC   The invention relates to in vitro identification (M1) of genes expressed
CC   in the skin of humans or animals by subjecting a mixture of genetically
CC   encoded factors from skin, to serial analysis of gene expression (SAGE)
CC   so as to identify skin-expressed genes and quantify their expression.
CC   (M1) is useful for identifying genes involved in skin homeostasis; to
CC   determine skin homeostasis and to test agent (A) that maintains or
CC   promotes skin homeostasis or that can be used for treating skin
CC   disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC   ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC   rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC   skin. The present sequence is that of a human expressed sequence tag
CC   (EST) of the invention
XX
SQ   Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             20.0%;  Score 10;  DB 1;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 34;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAG 2095
              ||||||||||
Db         10 AAACACTAAG 1


RESULT 101
ABV65107/c
ID   ABV65107 standard; cDNA; 11 BP.
XX
AC   ABV65107;
XX
DT   21-OCT-2002  (first entry)
XX
DE   Human skin EST 2893.
XX
KW   Human; skin; dermatological; vulnerary; antipsoriatic; antiseborrhaeic;
KW   immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW   psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS   Homo sapiens.
XX
PN   WO200253774-A2.
XX
PD   11-JUL-2002.
XX
PF   20-DEC-2001; 2001WO-EP015179.
XX
PR   03-JAN-2001; 2001DE-01000127.
XX
PA   (HENK ) HENKEL KGAA.
XX
PI   Petersohn D,  Conradt M,  Hofmann K;
XX
DR   WPI; 2002-590638/63.
XX
PT   In vitro identification of skin-expressed genes, useful for determining
PT   homeostasis and identifying cosmetic or pharmaceutical agents against
PT   e.g. skin cancer.
XX
PS   Disclosure; Page 105; 1345pp; German.
XX
CC   The invention relates to in vitro identification (M1) of genes expressed
CC   in the skin of humans or animals by subjecting a mixture of genetically
CC   encoded factors from skin, to serial analysis of gene expression (SAGE)
CC   so as to identify skin-expressed genes and quantify their expression.
CC   (M1) is useful for identifying genes involved in skin homeostasis; to
CC   determine skin homeostasis and to test agent (A) that maintains or
CC   promotes skin homeostasis or that can be used for treating skin
CC   disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC   ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC   rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC   skin. The present sequence is that of a human expressed sequence tag
CC   (EST) of the invention
XX
SQ   Sequence 11 BP; 1 A; 2 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             20.0%;  Score 10;  DB 1;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 34;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2074 AGCCATCCAA 2083
              ||||||||||
Db         11 AGCCATCCAA 2


RESULT 102
ABV70910/c
ID   ABV70910 standard; cDNA; 11 BP.
XX
AC   ABV70910;
XX
DT   21-OCT-2002  (first entry)
XX
DE   Human skin EST 8696.
XX
KW   Human; skin; dermatological; vulnerary; antipsoriatic; antiseborrhaeic;
KW   immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW   psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS   Homo sapiens.
XX
PN   WO200253774-A2.
XX
PD   11-JUL-2002.
XX
PF   20-DEC-2001; 2001WO-EP015179.
XX
PR   03-JAN-2001; 2001DE-01000127.
XX
PA   (HENK ) HENKEL KGAA.
XX
PI   Petersohn D,  Conradt M,  Hofmann K;
```

XX
DR WPI; 2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Claim 24; Page 279; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 20.0%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2086 AAACACTAAG 2095
||||||||||
Db 10 AAACACTAAG 1

RESULT 103
ADK13992
ID ADK13992 standard; DNA; 11 BP.
XX
AC ADK13992;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human methyl-CpG-binding protein 2, MECP2, mutation #1.
XX
KW human; Rett syndrome; methyl-CpG-binding protein 2; MECP2;
KW neurodevelopmental disease; autism; non-syndromic mental retardation;
KW idiopathic neonatal encephalopathy; idiopathic infantile spasm;
KW idiopathic cerebral palsy; Angelman syndrome; schizophrenia; ds.
XX
OS Homo sapiens.
XX
PN US6709817-B1.
XX
PD 23-MAR-2004.
XX
PF 07-SEP-2000; 2000US-00657013.
XX
PR 07-SEP-1999; 99US-0152778P.
XX
PA (BAYU) BAYLOR COLLEGE MEDICINE.
XX
PI Zoghbi HY, Van Den Veyver IB, Amir R, Francke U;
XX
DR WPI; 2004-256068/24.
XX
PT Screening human for Rett syndrome comprises detecting mutation in nucleic
PT acid sequence encoding methyl-CpG-binding protein 2 (MECP2).
XX
PS Disclosure; SEQ ID NO 94; 125pp; English.
XX
CC The invention relates to a method of screening a human for Rett syndrome
CC comprising detecting a mutation in a nucleic acid sequence encoding
CC methyl-CpG-binding protein 2 (MECP2). The method is useful for screening
CC a human for Rett syndrome. The method is useful for screening
CC neurodevelopmental diseases such as Rett syndrome, autism, non-syndromic
CC mental retardation, idiopathic neonatal encephalopathy, idiopathic
CC infantile spasms, idiopathic cerebral palsy, Angelman syndrome and
CC schizophrenia. The present sequence represents a mutation in the human
CC methyl-CpG-binding protein 2, MECP2, DNA
XX
SQ Sequence 11 BP; 6 A; 1 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 20.0%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2059 AGAGCAAAAG 2068
||||||||||
Db 1 AGAGCAAAAG 10

RESULT 104
ADQ35744/c
ID ADQ35744 standard; DNA; 11 BP.
XX
AC ADQ35744;
XX
DT 23-SEP-2004 (first entry)
XX
DE Human hair-bearing skin-associated DNA fragment SEQ ID NO 561.
XX
KW hair-bearing skin; human; serial analysis of gene expression; SAGE;
KW homeostasis; cosmetic; pharmaceutical; biochip; ds.
XX
OS Homo sapiens.
XX
PN DE10260931-A1.
XX
PD 08-JUL-2004.
XX
PF 20-DEC-2002; 2002DE-01060931.
XX
PR 20-DEC-2002; 2002DE-01060931.
XX
PA (HENK) HENKEL KGAA.
XX
PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
PI Conradt M, Hofmann K;
XX
DR WPI; 2004-518857/50.
XX
PT In vitro identification of genes important for hair-bearing skin, useful
PT for assessing homeostasis and in screening for pharmaceutical or cosmetic
PT agents, based on differential expression analysis.
XX
PS Claim 5; SEQ ID NO 561; 250pp; German.
XX
CC This invention describes a novel in vitro method for identifying genes
CC that are significant for hair-bearing skin in humans. The method
CC comprises recovering, from hair-bearing skin, a first mixture of
CC genetically expressed (transcribed and optionally translated) factors
CC (i.e. proteins, mRNA or their fragments), recovering a second, similar
CC mixture from skin on which hair does not grow and subjecting both
CC mixtures to serial analysis of gene expression (SAGE) to identify those
CC genes for which expression is markedly different between the two types of
CC skin. The invention also describes in vitro methods for determining
CC homeostasis of human hair-bearing skin and for determining activity of
CC cosmetic and pharmaceutical agents for use against disorders or
CC disturbances of the homeostasis of human hair-bearing skin. A biochip and
CC a test kit comprising a solid support (flexible or rigid) with
CC immobilised probes are also described for determining homeostasis. The
CC hair-bearing skin is from the scalp and the other skin is from the face.
CC The method allows identification of as many as possible of the genes
CC important for hair-bearing skin, and therefore, of a very wide range of
CC potential therapeutic and cosmetic agents. ADQ35184-ADQ36518 represent
CC human DNA Tag fragments used to identify genes associated with hair-
CC bearing skin.

```
XX
SQ   Sequence 11 BP; 2 A; 4 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match           20.0%;  Score 10;  DB 1;  Length 11;
  Best Local Similarity  100.0%;  Pred. No. 34;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2068 GACTTGAGCC 2077
              ||||||||||
Db         11 GACTTGAGCC 2


RESULT 105
ABI67934/c
ID   ABI67934 standard; DNA; 12 BP.
XX
AC   ABI67934;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 367907 for detecting SNP TSC0056643.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 367907; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 3 A; 1 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match           20.0%;  Score 10;  DB 1;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 39;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2085 GAAACACTAA 2094
              ||||||||||
Db         12 GAAACACTAA 3


RESULT 106
ADF78682/c
ID   ADF78682 standard; DNA; 12 BP.
XX
AC   ADF78682;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Chromosomal abnormality detection-related PCR primer 263.
XX
KW   chromosomal abnormality; maternal locus; genetic disorder; foetus;
KW   mutation; translocation; transversion; monosomy; trisomy; trisomy 21;
KW   chromosome 21; Down's Syndrome; anueoplodies; chromosome deletion;
KW   chromosome addition; chromosome amplification; chromosome translocation;
KW   chromosome rearrangement; single nucleotide polymorphism detection;
KW   SNP detection; pregnant female; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003074723-A2.
XX
PD   12-SEP-2003.
XX
PF   28-FEB-2003; 2003WO-US006198.
XX
PR   01-MAR-2002; 2002US-0360232P.
PR   11-MAR-2002; 2002US-00093618.
PR   08-MAY-2002; 2002US-0378354P.
XX
PA   (DHAL/) DHALLAN R.
XX
PI   Dhallan R;
XX
DR   WPI; 2003-845073/78.
XX
PT   Detection of chromosomal abnormalities e.g. Down's Syndrome, non-
PT   invasively in a fetus, comprises forming a ratio of amounts of alleles at
PT   a locus of interest and a different heterozygous locus.
XX
PS   Example 11; Page 241; 164pp; English.
XX
CC   This invention relates to a novel method of detecting chromosomal
CC   abnormalities by determining the sequence of alleles of a locus of
CC   interest from template DNA, determining which alleles are present and
CC   comparing to amounts of alleles at a different, selected heterozygous
CC   locus (for example on another chromosome or a maternal locus); relative
CC   amounts are expressed as a ratio indicating presence or absence of the
CC   abnormality. The method is useful for the detection of genetic disorders,
CC   especially in a foetus, including chromosomal abnormalities and
CC   mutations, for example translocations, transversions, monosomies,
CC   trisomies (for example trisomy 21 in which an additional copy of
CC   chromosome 21 results in Down's Syndrome) and other anueoplodies,
CC   deletions, additions, amplifications, translocations and rearrangements.
CC   It can be used to detect any alterations in a gene sequence, especially
CC   single nucleotide polymorphisms (SNPs), and may be used to detect
CC   numerous abnormalities simultaneously, for example if several SNPs are
CC   associated with a particular disease. The method provides a rapid, non-
CC   invasive method for determining the sequence of DNA from a foetus using a
CC   sample from a pregnant female, for example to detect genetic disorders as
CC   above or to determine if a foetus is a carrier of a disease or
CC   predisposed to a disease.
XX
SQ   Sequence 12 BP; 4 A; 3 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match           20.0%;  Score 10;  DB 1;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 39;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2066 AAGACTTGAG 2075
              ||||||||||
Db         10 AAGACTTGAG 1


Search completed: November  8, 2004, 15:24:46
```

Job time : 1 secs

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: November 8, 2004, 15:27:48 ; Search time 0.001 Seconds
(without alignments)
37.800 Million cell updates/sec

Title: us-10-655-847-18
Perfect score: 50
Sequence: 1 ttcagagcaaaagacttgag.....aaacactaagctctctgggc 50

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 23 seqs, 378 residues

Total number of hits satisfying chosen parameters: 46

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 23 summaries

Database : rnpbdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
c	1	20	40.0	20	1	US-10-160-807-71	Sequence 71, Appl
c	2	20	40.0	20	1	US-10-160-807-72	Sequence 72, Appl
c	3	20	40.0	20	1	US-10-160-807-73	Sequence 73, Appl
	4	20	40.0	20	1	US-10-160-807-217	Sequence 217, App
	5	20	40.0	20	1	US-10-160-807-218	Sequence 218, App
	6	20	40.0	20	1	US-10-160-807-219	Sequence 219, App
c	7	20	40.0	20	1	US-10-655-847-71	Sequence 71, Appl
c	8	20	40.0	20	1	US-10-655-847-72	Sequence 72, Appl
c	9	20	40.0	20	1	US-10-655-847-73	Sequence 73, Appl
	10	20	40.0	20	1	US-10-655-847-217	Sequence 217, App
	11	20	40.0	20	1	US-10-655-847-218	Sequence 218, App
	12	20	40.0	20	1	US-10-655-847-219	Sequence 219, App
	13	13.8	27.6	17	1	US-10-138-674-3813	Sequence 3813, Ap
	14	13.8	27.6	17	1	US-10-287-949A-3813	Sequence 3813, Ap
c	15	10.4	20.8	13	1	US-09-771-933-195	Sequence 195, App
c	16	10.4	20.8	13	1	US-09-771-933-196	Sequence 196, App
c	17	10	20.0	12	1	US-10-661-165-494	Sequence 494, App
	18	9.4	18.8	11	1	US-09-249-155-189	Sequence 189, App
	19	9.4	18.8	11	1	US-10-314-322-189	Sequence 189, App
	20	9.4	18.8	11	1	US-10-450-797-12	Sequence 12, Appl
c	21	9.4	18.8	11	1	US-10-450-797-323	Sequence 323, App
	22	9.4	18.8	11	1	US-10-055-536-17	Sequence 17, Appl
	23	9.4	18.8	11	1	US-10-055-536-32	Sequence 32, Appl

ALIGNMENTS

RESULT 1
US-10-160-807-71/c
; Sequence 71, Application US/10160807
; Publication No. US20030224514A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
; FILE REFERENCE: RTS-0189
; CURRENT APPLICATION NUMBER: US/10/160,807
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-807-71

Query Match 40.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.14;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2056 TTCAGAGCAAAAGACTTGAG 2075
              ||||||||||||||||||||
Db         20 TTCAGAGCAAAAGACTTGAG 1
```

RESULT 2
US-10-160-807-72/c
; Sequence 72, Application US/10160807
; Publication No. US20030224514A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
; FILE REFERENCE: RTS-0189
; CURRENT APPLICATION NUMBER: US/10/160,807
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-807-72

Query Match 40.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.14;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2073 GAGCCATCCAAAGAAACACT 2092
              ||||||||||||||||||||
Db         20 GAGCCATCCAAAGAAACACT 1
```

RESULT 3
US-10-160-807-73/c
; Sequence 73, Application US/10160807
; Publication No. US20030224514A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
; FILE REFERENCE: RTS-0189
; CURRENT APPLICATION NUMBER: US/10/160,807
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 73
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-807-73

Query Match 40.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.14;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2086 AAACACTAAGCTCTCTGGGC 2105
||||||||||||||||||||
Db 20 AAACACTAAGCTCTCTGGGC 1

RESULT 4
US-10-160-807-217
; Sequence 217, Application US/10160807
; Publication No. US20030224514A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
; FILE REFERENCE: RTS-0189
; CURRENT APPLICATION NUMBER: US/10/160,807
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 217
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-807-217

Query Match 40.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.14;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2056 TTCAGAGCAAAAGACTTGAG 2075
||||||||||||||||||||
Db 1 TTCAGAGCAAAAGACTTGAG 20

RESULT 5
US-10-160-807-218
; Sequence 218, Application US/10160807
; Publication No. US20030224514A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
; FILE REFERENCE: RTS-0189
; CURRENT APPLICATION NUMBER: US/10/160,807
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 218
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-807-218

Query Match 40.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.14;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2073 GAGCCATCCAAAGAAACACT 2092
||||||||||||||||||||
Db 1 GAGCCATCCAAAGAAACACT 20

RESULT 6
US-10-160-807-219
; Sequence 219, Application US/10160807
; Publication No. US20030224514A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
; FILE REFERENCE: RTS-0189
; CURRENT APPLICATION NUMBER: US/10/160,807
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 219
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-807-219

Query Match 40.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.14;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2086 AAACACTAAGCTCTCTGGGC 2105
||||||||||||||||||||
Db 1 AAACACTAAGCTCTCTGGGC 20

RESULT 7
US-10-655-847-71/c
; Sequence 71, Application US/10655847
; Publication No. US20040063129A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
; FILE REFERENCE: RTS-0189
; CURRENT APPLICATION NUMBER: US/10/655,847
; CURRENT FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: US/10/160,807
; PRIOR FILING DATE: 2003-09-05
; NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-655-847-71

Query Match 40.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.14;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2056 TTCAGAGCAAAAGACTTGAG 2075
||||||||||||||||||||
Db 20 TTCAGAGCAAAAGACTTGAG 1

RESULT 8
US-10-655-847-72/c
; Sequence 72, Application US/10655847
; Publication No. US20040063129A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
; FILE REFERENCE: RTS-0189
; CURRENT APPLICATION NUMBER: US/10/655,847
; CURRENT FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: US/10/160,807
; PRIOR FILING DATE: 2003-09-05
; NUMBER OF SEQ ID NOS: 296

```
; SEQ ID NO 72
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-655-847-72

  Query Match             40.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 0.14;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2073 GAGCCATCCAAAGAAACACT 2092
              ||||||||||||||||||||
Db         20 GAGCCATCCAAAGAAACACT 1


RESULT 9
US-10-655-847-73/c
; Sequence 73, Application US/10655847
; Publication No. US20040063129A1
; GENERAL INFORMATION:
;  APPLICANT: William Gaarde
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
;  FILE REFERENCE: RTS-0189
;  CURRENT APPLICATION NUMBER: US/10/655,847
;  CURRENT FILING DATE:  2003-09-05
;  PRIOR APPLICATION NUMBER: US/10/160,807
;  PRIOR FILING DATE: 2003-09-05
;  NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 73
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-655-847-73

  Query Match             40.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 0.14;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAGCTCTCTGGGC 2105
              ||||||||||||||||||||
Db         20 AAACACTAAGCTCTCTGGGC 1


RESULT 10
US-10-655-847-217
; Sequence 217, Application US/10655847
; Publication No. US20040063129A1
; GENERAL INFORMATION:
;  APPLICANT: William Gaarde
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
;  FILE REFERENCE: RTS-0189
;  CURRENT APPLICATION NUMBER: US/10/655,847
;  CURRENT FILING DATE:  2003-09-05
;  PRIOR APPLICATION NUMBER: US/10/160,807
;  PRIOR FILING DATE: 2003-09-05
;  NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 217
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-655-847-217

  Query Match             40.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 0.14;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2056 TTCAGAGCAAAAGACTTGAG 2075
              ||||||||||||||||||||
Db          1 TTCAGAGCAAAAGACTTGAG 20


RESULT 11
US-10-655-847-218
; Sequence 218, Application US/10655847
; Publication No. US20040063129A1
; GENERAL INFORMATION:
;  APPLICANT: William Gaarde
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
;  FILE REFERENCE: RTS-0189
;  CURRENT APPLICATION NUMBER: US/10/655,847
;  CURRENT FILING DATE:  2003-09-05
;  PRIOR APPLICATION NUMBER: US/10/160,807
;  PRIOR FILING DATE: 2003-09-05
;  NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 218
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-655-847-218

  Query Match             40.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 0.14;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2073 GAGCCATCCAAAGAAACACT 2092
              ||||||||||||||||||||
Db          1 GAGCCATCCAAAGAAACACT 20


RESULT 12
US-10-655-847-219
; Sequence 219, Application US/10655847
; Publication No. US20040063129A1
; GENERAL INFORMATION:
;  APPLICANT: William Gaarde
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
;  FILE REFERENCE: RTS-0189
;  CURRENT APPLICATION NUMBER: US/10/655,847
;  CURRENT FILING DATE:  2003-09-05
;  PRIOR APPLICATION NUMBER: US/10/160,807
;  PRIOR FILING DATE: 2003-09-05
;  NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 219
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-655-847-219

  Query Match             40.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 0.14;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2086 AAACACTAAGCTCTCTGGGC 2105
              ||||||||||||||||||||
Db          1 AAACACTAAGCTCTCTGGGC 20


RESULT 13
US-10-138-674-3813
; Sequence 3813, Application US/10138674
; Publication No. US20040077565A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3813
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-138-674-3813

  Query Match             27.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 1.8;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2072 TGAGCCATCCAAAGAAA 2088
              :||||||:| |||| ||
Db          1 UGAGCCAUCAAAAGGAA 17


RESULT 14
US-10-287-949A-3813
; Sequence 3813, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3813
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-3813

  Query Match             27.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 1.8;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2072 TGAGCCATCCAAAGAAA 2088
              :||||||:| |||| ||
Db          1 UGAGCCAUCAAAAGGAA 17


RESULT 15
US-09-771-933-195/c
; Sequence 195, Application US/09771933
; Publication No. US20030023387A1
; GENERAL INFORMATION:
;  APPLICANT: Gill-Garrison, Rosalynn D
;  APPLICANT:  Martin, Christopher J
;  APPLICANT:  Sanchez-Felix, Manuel V
;  TITLE OF INVENTION: Computer-assisted Means for Assessing Lifestyle Risk
;  TITLE OF INVENTION:  Factors
;  FILE REFERENCE: 620-130
;  CURRENT APPLICATION NUMBER: US/09/771,933
;  CURRENT FILING DATE:  2001-01-30
;  NUMBER OF SEQ ID NOS: 205
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 195
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Probe
US-09-771-933-195

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 8.1;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2094 AGCTCTCTGGGC 2105
              |||| |||||||
Db         13 AGCTATCTGGGC 2


RESULT 16
US-09-771-933-196/c
; Sequence 196, Application US/09771933
; Publication No. US20030023387A1
; GENERAL INFORMATION:
;  APPLICANT: Gill-Garrison, Rosalynn D
;  APPLICANT:  Martin, Christopher J
;  APPLICANT:  Sanchez-Felix, Manuel V
;  TITLE OF INVENTION: Computer-assisted Means for Assessing Lifestyle Risk
;  TITLE OF INVENTION:  Factors
;  FILE REFERENCE: 620-130
;  CURRENT APPLICATION NUMBER: US/09/771,933
;  CURRENT FILING DATE:  2001-01-30
;  NUMBER OF SEQ ID NOS: 205
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 196
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Probe
US-09-771-933-196

  Query Match             20.8%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 8.1;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2094 AGCTCTCTGGGC 2105
              |||| |||||||
Db         13 AGCTGTCTGGGC 2


RESULT 17
US-10-661-165-494/c
; Sequence 494, Application US/10661165
; Publication No: US20040137470A1
; GENERAL INFORMATION:
;  APPLICANT: Dhallan, Ravinder S.
;  TITLE OF INVENTION: METHODS FOR DETECTION OF GENETIC
;  TITLE OF INVENTION:  DISORDERS
;  FILE REFERENCE: 543312000420
;  CURRENT APPLICATION NUMBER: US/10/661,165
;  CURRENT FILING DATE:  2003-09-11
;  PRIOR APPLICATION NUMBER: PCT/US03/06198
;  PRIOR FILING DATE: 2003-02-28
;  PRIOR APPLICATION NUMBER: US 60/378,354
;  PRIOR FILING DATE: 2002-05-08
;  PRIOR APPLICATION NUMBER: US 10/093,618
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/360,232
;  PRIOR FILING DATE: 2002-03-01
;  PRIOR APPLICATION NUMBER: PCT/US03/27308
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/376,770
```

; PRIOR FILING DATE: 2003-02-28
; NUMBER OF SEQ ID NOS: 628
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 494
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-661-165-494

Query Match 20.0%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2066 AAGACTTGAG 2075
||||||||||
Db 10 AAGACTTGAG 1

RESULT 18
US-09-249-155-189
; Sequence 189, Application US/09249155
; Publication No. US20030037345A1
; GENERAL INFORMATION:
; APPLICANT: Heber-Katz, Ellen
; TITLE OF INVENTION: Compositions and Methods for Wound
; TITLE OF INVENTION: Healing
; FILE REFERENCE: 00486.78503
; CURRENT APPLICATION NUMBER: US/09/249,155
; CURRENT FILING DATE: 1999-02-12
; EARLIER APPLICATION NUMBER: 60/074,737
; EARLIER FILING DATE: 1998-02-13
; EARLIER APPLICATION NUMBER: 60/097,937
; EARLIER FILING DATE: 1998-08-26
; EARLIER APPLICATION NUMBER: 60/102,051
; EARLIER FILING DATE: 1998-09-28
; NUMBER OF SEQ ID NOS: 254
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 189
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-249-155-189

Query Match 18.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 14;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2087 AACACTAAGCT 2097
||||| |||||
Db 1 AACACCAAGCT 11

RESULT 19
US-10-314-322-189
; Sequence 189, Application US/10314322
; Publication No. US20030229911A1
; GENERAL INFORMATION:
; APPLICANT: Heber-Katz, Ellen
; TITLE OF INVENTION: Compositions and Methods for Wound
; TITLE OF INVENTION: Healing
; FILE REFERENCE: 000486.00016
; CURRENT APPLICATION NUMBER: US/10/314,322
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: US 60/074,737
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/097,937
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: US 60/102,051
; PRIOR FILING DATE: 1998-09-28
; PRIOR APPLICATION NUMBER: US 09/249,155
; PRIOR FILING DATE: 1999-02-12
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 189
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-314-322-189

Query Match 18.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 14;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2087 AACACTAAGCT 2097
||||| |||||
Db 1 AACACCAAGCT 11

RESULT 20
US-10-450-797-12
; Sequence 12, Application US/10450797
; Publication No. US20040142335A1
; GENERAL INFORMATION:
; APPLICANT: Petersohn, Dirk
; APPLICANT: Conradt, Marcus
; APPLICANT: Hofmann, Kay
; TITLE OF INVENTION: METHOD FOR DETERMINING SKIN STRESS OR SKIN AGEING IN VITRO
; FILE REFERENCE: HENK-0041
; CURRENT APPLICATION NUMBER: US/10/450,797
; CURRENT FILING DATE: 2003-12-04
; PRIOR APPLICATION NUMBER: PCT/EP01/15178
; PRIOR FILING DATE: 2001-12-20
; PRIOR APPLICATION NUMBER: DE 101 00 121.5
; PRIOR FILING DATE: 2001-01-03
; NUMBER OF SEQ ID NOS: 1435
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-450-797-12

Query Match 18.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 14;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2071 TTGAGCCATCC 2081
||||||||| ||
Db 1 TTGAGCCAGCC 11

RESULT 21
US-10-450-797-323/c
; Sequence 323, Application US/10450797
; Publication No. US20040142335A1
; GENERAL INFORMATION:
; APPLICANT: Petersohn, Dirk
; APPLICANT: Conradt, Marcus
; APPLICANT: Hofmann, Kay
; TITLE OF INVENTION: METHOD FOR DETERMINING SKIN STRESS OR SKIN AGEING IN VITRO
; FILE REFERENCE: HENK-0041
; CURRENT APPLICATION NUMBER: US/10/450,797
; CURRENT FILING DATE: 2003-12-04
; PRIOR APPLICATION NUMBER: PCT/EP01/15178
; PRIOR FILING DATE: 2001-12-20
; PRIOR APPLICATION NUMBER: DE 101 00 121.5
; PRIOR FILING DATE: 2001-01-03
; NUMBER OF SEQ ID NOS: 1435
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 323
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-450-797-323

Query Match 18.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 14;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2056 TTCAGAGCAAA 2066
             ||||||| |||
Db         11 TTCAGAGAAAA 1
```

RESULT 22
US-10-055-536-17
; Sequence 17, Application US/10055536
; Publication No. US20040191262A1
; GENERAL INFORMATION:
; APPLICANT: DUTTA, Sukanta K.
; APPLICANT: BISWAS, Biswajit
; APPLICANT: VEMULAPALLI, Ramesh
; TITLE OF INVENTION: A SIZE-VARIABLE STRAIN-SPECIFIC PROTECTIVE ANTIGEN FOR
; TITLE OF INVENTION: POTOMAC HORSE FEVER
; FILE REFERENCE: 8172-9016
; CURRENT APPLICATION NUMBER: US/10/055,536
; CURRENT FILING DATE: 2002-01-23
; PRIOR APPLICATION NUMBER: US/09/157,257
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/059,252
; PRIOR FILING DATE: 1997-09-18
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 17
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: :
US-10-055-536-17

Query Match 18.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 14;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2082 AAAGAAACACT 2092
             ||||||| |||
Db          1 AAAGAAATACT 11
```

RESULT 23
US-10-055-536-32
; Sequence 32, Application US/10055536
; Publication No. US20040191262A1
; GENERAL INFORMATION:
; APPLICANT: DUTTA, Sukanta K.
; APPLICANT: BISWAS, Biswajit
; APPLICANT: VEMULAPALLI, Ramesh
; TITLE OF INVENTION: A SIZE-VARIABLE STRAIN-SPECIFIC PROTECTIVE ANTIGEN FOR
; TITLE OF INVENTION: POTOMAC HORSE FEVER
; FILE REFERENCE: 8172-9016
; CURRENT APPLICATION NUMBER: US/10/055,536
; CURRENT FILING DATE: 2002-01-23
; PRIOR APPLICATION NUMBER: US/09/157,257
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/059,252
; PRIOR FILING DATE: 1997-09-18
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 32
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Ehrlichia risticii
US-10-055-536-32

Query Match 18.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 14;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2082 AAAGAAACACT 2092
             ||||||| |||
Db          1 AAAGAAATACT 11
```

Search completed: November 8, 2004, 15:27:48
Job time : 0.001 secs